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1. INTRODUCTION 
 
In recent years cancer has become less of an enigma. After decades of rapid advances 
in cancer research, several lines of evidence indicate that during the course of tumor 
progression, cancer cells gradually acquire a number of dynamic genetic alterations, 
that drive the progressive transformation of normal human cells into highly 
malignant derivatives [1]. 
Most tumors are formed by a stepwise progression of cells from a transformed 
but minimally altered state, that can grow and form nodules or polyps (in solid 
tumors) to a multiply deviated state that is capable of unlimited growth, manipulation 
of local environment, invasion of surrounding tissues and escape into the circulation 
to found new colonies of secondary tumors and metastases. Such a progression 
involves diverse molecular and morphological changes. In fact the foundation has set 
in the discovery of mutations that produce oncogenes with dominant gain of function 
and tumor suppressor genes with recessive loss of function. 
Over the past decades, the research has revealed a small number of molecular, 
biochemical, and cellular traits—acquired capabilities—shared by most and perhaps 
all types of human cancer. Our faith in such simplification derives directly from the 
teachings of cell biology that virtually all mammalian cells carry a similar molecular 
machinery regulating their proliferation, differentiation, and death. 
These observations have been rendered more concrete by a large body of work 
indicating that the genomes of tumor cells are invariably altered at multiple sites, 
having suffered disruption through lesions as both subtle point mutations and 
obvious changes in chromosome complement. Transformation of cultured cells is 
itself a multistep process: rodent cells require at least two introduced genetic changes 
before they acquire tumorigenic competence, while their human counterparts are 
more difficult to transform. 
The barriers to development of cancer are embodied in a teleology: cancer cells 
have defects in regulatory circuits that govern normal cell proliferation and 
homeostasis. The vast catalog of cancer cell genotypes is a manifestation of six 
essential alterations in cell physiology [2], that collectively dictate malignant growth: 
1. self-sufficiency in growth signals,  
2. insensitivity to growth-inhibitory (antigrowth) signals,  
3. evasion of programmed cell death (apoptosis),  
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4. limitless replicative potential,  
5. self-sustained supply of nutrients and oxygen (angiogenesis), 
6. capacity to tissue invasion and metastasis.  
Each of these physiologic changes—novel capabilities acquired during tumor 
development—represents the successful breaching of an anticancer defense 
mechanism hardwired into cells and tissues. These six capabilities are shared by 
several types of human tumors (Fig. 1). 
 
 
Figure 1. Acquired capability of cancer cells 
 
1.1. Hallmark of Cancer Cells 
 
1.1.1. Self-sufficiency in Growth Signals 
Normal cells require mitogenic growth signals (GS) before they can move from 
a quiescent state into an active proliferative state. These signals are transmitted into 
cell by transmembrane receptors that bind distinctive classes of signaling molecules: 
diffusible growth factors, extracellular matrix components, and cell-to-cell 
adhesion/interaction molecules. No type of normal cell can proliferate in the absence 
of such stimulatory signals. 
Dependence on growth signaling is apparent when propagating normal cells in 
culture, which typically proliferate only when supplied with appropriate diffusible 
mitogenic factors and a proper substratum for their integrins. Such a behaviour 
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contrasts strongly with that of tumor cells, which invariably show a greatly reduced 
dependence on exogenous growth stimulation. The conclusion is that tumor cells 
generate many of their own growth signals, thereby reducing their dependence on 
stimulation from their normal tissue microenvironment. This liberation from 
dependence on exogenously derived signals disrupts a critically important 
homeostatic mechanism that normally operates to ensure a proper behaviour of the 
various cell types within a tissue. 
Three common molecular strategies for achieving autonomy are evident, 
involving alteration of extracellular growth signals, of transcellular transducers of 
those signals, or of intracellular circuits that translate those signals into action.  
While most soluble mitogenic growth factors (GFs) are made by one cell type 
in order to stimulate proliferation of another—the process of heterotypic signaling—
many cancer cells acquire the ability to synthesize GFs, to which they are responsive, 
creating a positive feedback signaling loop often termed autocrine stimulation. 
Clearly, the manufacture of a GF by a cancer cell obviates dependence on factors 
from other cells within the tissue. The cell surface receptors, that transduce growth 
stimulatory signals into the cell interior, are themselves targets of deregulation 
during tumor pathogenesis. GF receptors, often carrying tyrosine kinase activities in 
their cytoplasmic domains, are overexpressed in many cancers. 
 
1.1.2. Insensitivity to Antigrowth Signals 
Within a normal tissue, multiple antiproliferative signals operate to maintain 
cellular quiescence and tissue homeostasis. These signals include both soluble 
growth inhibitors and immobilized inhibitors embedded in extracellular matrix and 
on the surfaces of nearby cells. These growth-inhibitory signals, like their positively 
acting counterparts, are received by transmembrane cell surface receptors coupled to 
intracellular signaling circuits. Antigrowth signals can block proliferation by two 
distinct mechanisms. Cells may be forced out of the active proliferative cycle into the 
quiescent (G0) state from which they may reemerge on some future occasion when 
extracellular signals permit. Alternatively, cells may be induced to permanently 
relinquish their proliferative potential by being induced to enter into postmitotic 
states, usually associated with acquisition of specific differentiation-associated traits. 
Incipient cancer cells must evade these antiproliferative signals if they are to prosper. 
Much of the circuitry that enables normal cells to respond to antigrowth signals is 
 4 
associated with the cell cycle clock, specifically the components governing the 
transit of the cell through the G1 phase of its growth cycle. Cells monitor their 
external environment during this period and, on the basis of sensed signals, decide 
whether to proliferate, to be quiescent, or to enter into a postmitotic state. Cell 
proliferation depends on more than an avoidance of cytostatic antigrowth signals, 
involved in signaling pathways. These converge on retinoblastoma-related proteins, 
which govern cell transit through the G1 phase of the cell division cycle. 
Hypophosphorylated retinoblastoma blocks proliferation by sequestering and altering 
the function of E2F transcription factors, which control the expression of a wide 
variety of genes essential for progression from G1 to S phase. 
 
1.1.3. Evading Apoptosis 
The ability of tumor cell populations to expand in number is determined not 
only by the rate of cell proliferation but also by the rate of cell attrition. Programmed 
cell death—apoptosis—represents a major source of this attrition. The apoptotic 
program is present in latent form in virtually all cell types throughout the body. Once 
triggered by a variety of physiologic signals, this program unfolds in a series of 
steps. Cellular membranes are disrupted, the cytoplasmic and nuclear skeletons are 
broken down, the cytosol is extruded, the chromosomes are degraded and the nucleus 
is fragmented. The apoptotic machinery can be broadly divided into two classes of 
components—sensors and effectors. The sensors are responsible for monitoring the 
extracellular and intracellular environment for conditions of normality or 
abnormality that influence whether a cell should live or die. These signals regulate 
the second class of components, which function as effectors of apoptotic death. The 
sentinels include cell surface receptors that bind survival or death factors. 
Intracellular sensors monitor the cell‘s well-being and activate the death 
pathway in response to detecting abnormalities, including DNA damage, signaling 
imbalance provoked by oncogene action, survival factor insufficiency, or hypoxia. 
Further, the life of most cells is in part maintained by cell–matrix and cell–cell 
adherence-based survival signals whose abrogation elicits apoptosis. Both soluble 
and immobilized apoptotic regulatory signals likely reflect the needs of tissues to 
maintain their constituent cells in appropriate architectural configurations. 
Altering components of the apoptotic machinery can dramatically affect the 
dynamics of tumor progression, providing a rationale for the inactivation of this 
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machinery during tumor development [3]. Resistance to apoptosis can be acquired by 
cancer cells through a variety of strategies. Apoptosis can be inhibited by the 
activation of prosurvival signaling pathways, while, at same time, the decreased 
expression of proapoptotic factors. Signals evoked by other abnormalities, including 
hypoxia and oncogene hyperexpression, are also centralized in part via p53 to the 
apoptotic machinery. 
 
1.1.4. Limitless Replicative Potential 
Three acquired capabilities—growth signal autonomy, insensitivity to 
antigrowth signals, and resistance to apoptosis—all lead to an uncoupling of a cell‘s 
growth program from signals in its environment. In principle, the resulting 
deregulated proliferation program should suffice to enable the generation of the vast 
cell populations that constitute macroscopic tumors. This acquired disruption of cell-
to-cell signaling does not ensure expansive tumor growth. Many and perhaps all 
types of mammalian cells carry an intrinsic, cell-autonomous program that limits 
their multiplication. This program appears to operate independently of the cell-to-cell 
signaling pathways described above. It too must be disrupted in order for a clone of 
cells to expand to a size that constitutes a macroscopic, life threatening tumor. Cells 
in culture have a finite replicative potential. Once such cell populations have 
progressed through a certain number of doublings, they stop growing—a process 
termed senescence. The senescence of cultured human fibroblasts can be 
circumvented by disabling their pRb and p53 tumor suppressor proteins, enabling 
these cells to continue multiplying for additional generations until they enter into a 
second state termed crisis. The crisis state is characterized by massive cell death, 
karyotypic disarray associated with end-to-end fusion of chromosomes, and the 
occasional emergence of a variant cell that has acquired the ability to multiply 
without limit, the trait termed immortalization. Most types of tumor cells that are 
propagated in culture appear to be immortalized, suggesting that limitless replicative 
potential is a phenotype that was acquired in vivo during tumor progression and was 
essential for the development of their malignant growth state. This result suggests 
that at some point during the course of multistep tumor progression, evolving 
premalignant cell populations, exhaust their endowment of allowed doublings and 
can only complete their tumorigenic agenda by breaching the mortality barrier and 
acquiring unlimited replicative potential. The evolving premalignant and malignant 
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cell populations evidence chronic, widespread apoptosis and consequently suffer 
considerable cell attrition concomitant with cell accumulation. Thus, the number of 
cells in a tumor greatly under-represents the cell generations required to produce it, 
the generational limit of normal somatic cells as a barrier to cancer. Replicative 
generations are counted by the 50–100 bp loss telomeric DNA from the ends of 
every chromosome during each cell cycle. This progressive shortening has been 
attributed to the inability of DNA polymerases to completely replicate the 3‘ ends of 
chromosomal DNA during each S phase. The progressive erosion of telomeres 
through successive cycles of replication eventually causes them to lose their ability 
to protect the ends of chromosomal DNA. The unprotected chromosomal ends 
participate in end-to-end chromosomal fusions, yielding the karyotypic disarray 
associated with crisis and resulting, almost inevitably, in the death of the affected 
cell. Telomere maintenance is evident in virtually all types of malignant cells; 85%–
90% of them succeed in doing so by upregulating expression of the telomerase 
enzyme, which adds hexanucleotide repeats onto the ends of telomeric DNA, while 
the remainder have invented a way of activating a mechanism, termed ALT, which 
appears to maintain telomeres through recombination-based interchromosomal 
exchanges of sequence information transitory. 
 
1.1.5. Sustained Angiogenesis 
The oxygen and nutrients supplied by the vasculature are crucial for cell 
function and survival, obligating virtually all cells in a tissue to reside within 100 
mm of a capillary blood vessel. During organogenesis, this closeness is ensured by 
coordinated growth of vessels and parenchyma. Once a tissue is formed, the growth 
of new blood vessels—the process of angiogenesis—is transitory and carefully 
regulated. Because of this dependence on nearby capillaries, it would seem plausible 
that proliferating cells within a tissue would have an intrinsic ability to encourage 
blood vessel growth. Angiogenic ability is acquired during tumor development via an 
angiogenic exchange from vascular quiescence.  
One common strategy for shifting the balance involves altered gene 
transcription. The coordinated expression of other pro- and anti-angiogenic signaling 
molecules, such as thrombosbondin, growth factors, integrin or plasmin, and their 
modulation by proteolysis, appear to reflect the complex homeostatic regulation of 
normal tissue angiogenesis and of vascular integrity. 
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1.1.6. Tissue Invasion and Metastasis 
During the development of most types of human cancer, primary tumor masses 
spawn pioneer cells that move out, invade adjacent tissues, and thence travel to 
distant sites where they may succeed in founding new colonies [4]. These distant 
settlements of tumor cells—metastases—are the cause of 90% of human cancer 
deaths. The capability for invasion and metastasis enables cancer cells to escape the 
primary tumor mass and colonize new terrain in the body where, at least initially, 
nutrients and space are not limiting. The newly formed metastases arise as amalgams 
of cancer cells and normal supporting cells conscripted from the host tissue. Several 
classes of proteins, involved in the cellular functions towards their surroundings in a 
tissue, are altered and possessed invasive or metastatic capabilities. The affected 
proteins include cell–cell adhesion molecules (CAMs)—notably members of the 
immunoglobulin and calcium-dependent cadherin families, both of which mediate 
cell-to-cell interactions—and integrins, which link cells to extracellular matrix 
substrates. 
The second general parameter of the invasive and metastatic capability involves 
extracellular proteases. Protease genes are upregulated, protease inhibitor genes are 
downregulated, and inactive zymogen forms of proteases are converted into active 
enzymes. Matrix-degrading proteases, such as metalloproteinase-2, are 
characteristically associated with the cell surface, by synthesis with a transmembrane 
domain, binding to specific protease receptors, or association with integrins. The 
matrix metalloproteinase-2 (MMP2) can degrade the matrix, providing cancer cells 
with access to the vasculature and lymphatic system, allowing tumor dissemination.  
 
1.2. Genome Instability 
 
The available evidence suggests that most of those physiologic changes are acquired, 
directly or indirectly, through changes in the genomes of cancer cells. But mutation 
of specific genes is an inefficient process, reflecting the unceasing, fastidious 
maintenance of genomic integrity by a complex array of DNA monitoring and repair 
enzymes. Malfunction of specific components of these genomic ―caretaker‖ systems 
has been invoked to explain this increased mutability. A growing number of genes 
involved in sensing and repairing DNA damage, or in assuring correct chromosomal 
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segregation during mitosis, is found to be lost in different cancers, labeling these 
caretakers as tumor suppressors. Their loss of function is envisioned to allow genome 
instability and variability and the generation of consequently mutant cells with 
selective advantages. 
These cancer-associated hallmark characteristics actually reflect genetic 
alterations in multiple ‗safeguard‘ genes of the cell, namely oncogenes and tumor 
suppressor genes. These genes are responsible for the regulation of signal 
transduction molecules, including among others receptor tyrosine kinases (RTKs), 
products of the Ras and Raf genes, and protein kinases, as mitogen-activated protein 
kinase (MAPK), phosphoinositide 3-kinase (PI3K) and Akt. These molecules in 
normal cells control the tight coordination of diverse processes such as cell survival, 
proliferation, growth, differentiation and motility. 
All of these proteins belong to various ‗signal transduction‘ pathways, which 
refer to the flow of biological information from the cell‘s micro-environment 
(extracellular matrix, neighbouring cells) via detection systems, such as surface 
receptors and through intermediate molecules, inside the cell (Fig. 2). The latter 
include a wide array of intracellular elements interacting through cascades of 
chemical signals and ultimately controlling the activities of specific intracellular 
effectors, resulting in the tight coordination of fundamental processes of cellular life. 
 
Figure 2. Signal transduction pathways 
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Signaling pathways are not isolated from each other, but instead they are 
interconnected, forming a labyrinth of intersecting and overlapping networks, 
enhancing thus the robustness and diversity of signaling and permitting fine-tuning 
and amplification or attenuation of the output [5]. 
Advances in the understanding of aberrant signaling pathways in various types 
of cancers have directly promoted the development of targeted therapies, that is the 
development of drugs that influence the action and/or activity of a specific signaling 
molecule. Elucidation of the roles of many kinase signaling pathways in cancer, 
including growth factor receptors and their downstream effectors, along with the 
identification of kinases as an attractive drug-target class, has led to the expectation 
of innovating cancer-treatment strategies with more specific mechanisms of action 
than conventional chemotherapeutic agents. However, the crucial challenge to select 
appropriate targets/approaches in cancer therapeutics still remains. 
The genetic instability of many tumor diseases represents one of the most 
difficult obstacles to overcome. In the last decades, promising efforts have been 
made in the improvement of chemotherapy regimens through the development of 
novel and more selective therapeutic agents. However the massive exposure to a 
previous successful chemotherapy scheme activates multiple overlapping signal 
pathways, with the global effect to protect the cancer cells from further harm. 
Therefore, it is clear why the understanding of molecular mechanisms underlying the 
multi-factorial stress response is of great importance in the drug design phase of 
cancer therapy. From early 1990s, several groups [6-9] reported that the cells 
respond to stresses by increasing the synthesis of a number of molecular chaperones 
known as heat shock proteins (because they first were observed in cells exposed to 
high temperatures). 
 10 
2. HEAT SHOCK PROTEINS 
 
Heat shock proteins (HSPs) were first discovered in 1962 as a small set of highly 
evolutionary conserved family of proteins whose expression increased in response to 
a variety of different metabolic insults. Despite their designation, most of the HSPs 
are constitutively expressed and perform essential functions. Most important is their 
role as molecular chaperones, facilitating the synthesis and folding of proteins 
throughout the cell. In addition, HSPs have been showed to participate in proteins 
assembly, secretion, trafficking, protein degradation, and in the regulation of 
transcription factors and protein kinases [10-13]. Increased levels of HSPs after 
several types of stress plays a central role in cellular homeostasis [14] (Table 1). 
 
Table 1. Type of stresses in cellular homeostasis 
STRESS OR STRESSOR 
TYPE 
NAME OR DESCRIPTION 
Physical Heat (including fever, cold, several types of irradiation, including 
ultraviolet light, and magnetic fields) 
Oxygen 
Oxygen derived free radicals (reactive oxygen species), hydrogen 
peroxide, a shift from anaerobiosis to aerobiosis (e.g. reperfusion), 
hypoxia-anoxia (ischemia) 
pH Alkalosis, acidosis, pH shift 
Biologic Infection, inflammation, fever 
Psychological Emotion, emotional conflicts, hormonal imbalance (hypothalamic-
pituary, adrenal axis, and autonomic nervous system) 
Osmotic Changes in the concentrations of salt, sugar, and other osmolytes 
(hyperosmotic or hypoosmotic shock)  
Nutritional Starvation involving multiple nutritional components (carbon, glucose, 
nitrogen, phosphate, and nitrate) or anyone of these 
Antibiotics Puromycin, tetracycline, nalidixic acid, doxorubicin 
Alcohols Ethanol, methanol, butanol, propanol, octanol 
Metals Cadmium, copper, chromium, zinc, tin, aluminum, mercury, lead, 
nickel 
Mechanical Compression, shearing, stretching  
Other 
Desiccation, benzene and derivatives, phenol and derivatives, 
teratogens, carcinogens, mutagens, arsenite, arsenate, amino acid 
analogs, nicotine, anesthetics, insecticides, pesticides 
 
All organisms exhibit homeostatic-like responses when subjected to rapid 
changes in their environment. The ability of the organism to successfully adapt or 
acclimate to its new environment is critical to its survival, and likely represents an 
integral driving force in evolution. One well studied response to sudden adverse 
environmental changes is the so-called heat shock or stress response. When 
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confronted with physiologically relevant increases in temperature, cells from all 
organisms respond similarly by rapidly increasing the synthesis of a select group of 
proteins, the HSPs. Changes in the expression of the HSPs are controlled by a set of 
transcription factors referred to as heat shock factors (HSFs). The resultant increase 
and accumulation of the HSPs now gives the stressed cell added protection, thereby 
allowing for continued cell survival. In addition to increased temperatures, other 
insults also result in increased HSP expression. These include exposure of cells to 
various metals, amino acid analogues, hypoxia, and a large number of 
agents/treatments which result in reduced ATP levels. Therefore many adverse 
conditions lead to increased HSP expression, the heat shock response now is 
commonly referred to as the ―stress response.‖ Despite their designation as HSPs or 
stress proteins, almost all of these proteins are in fact synthesized in cells grown 
under normal conditions (i.e. constitutive) and that their expression increases (i.e. 
induced) after metabolic stress. The realization that many of the HSPs function as 
―molecular chaperones‖ helps explain why these proteins are so critical for normal 
growth, as well as the ability of the cell to survive different metabolic insults [15]. 
Specifically, in their role as molecular chaperones, the different HSPs facilitate the 
early stages of folding and assembly of other cellular proteins. Although they do not 
convey any information for the folding or assembly process, molecular chaperones 
act by stabilizing maturing polypeptides and thereby reduce the probability of 
incorrect folding or aggregation. Thus, under normal growth conditions where they 
are expressed at modest levels, members of the HSP family participate in the early 
stages of protein synthesis, protein folding, and the transport of newly synthesized 
proteins from the cytoplasm into different intracellular compartments (Fig. 3).  
Under conditions of stress, where protein folding/assembly events may be 
compromised, the increased expression and accumulation of the stress proteins 
facilitates the ability of cells to both repair and synthesize new proteins to replace 
those that were damaged after the particular metabolic insult. In addition to their 
critical role in cellular homeostasis, the stress response proteins are implicated in 
human disease. Various medical conditions, including fever, ischemia, hemodynamic 
overload or neurological injuries are well known activators of the stress response in 
vivo. The ability of the affected tissue or organ to mount a robust stress response is 
thought to be important for its survival and recovery. In infectious diseases, stress 
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proteins present within different pathogens are known to be major targets of our 
immune system. 
 
Figure 3. The HSP system 
 
Among the members of the family, the 90-kDa heat shock protein (Hsp90) is 
the most abundant, representing almost 1% of total cellular protein in unstressed cells 
[16], where it performs housekeeping functions, controlling the stability, maturation, 
activation, intracellular disposition and proteolytic turn-over of ―client proteins‖ [17]. 
 
 
Figure 4. Hsp90 and the six hallmarks of cancer cell 
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Unlike some of the other well characterized HSPs whose chaperone role 
involves their interaction with many cellular proteins, Hsp90 exhibits some 
selectivity for a distinct set of ―client proteins‖, including mutant p53, HER-2, 
HIF-1, Akt/PKB c-Raf -1, hTERT and CDK4 [18]. These are members of the ―most-
wanted‖ list of proteins considered responsible for the multiple hallmark traits of 
malignancy (Fig. 4, Table 2). 
 
Table 2. Hsp90 clients and the multiple hallmarks of cancer 
Cancer-associated Cellular Traits Hsp90 Client Proteins 
Self-sufficiency in growth signals 
MEK 
SRC tyrosine kinases 
Steroid hormone receptors 
Insensitivity to antigrowth signals 
Akt 
CDK2, CDK4 
HIF-1α 
RTKs 
SRC tyrosine kinases 
Steroid hormone receptors 
Evading apoptosis 
Akt 
RTKs 
Survivin 
Tissue invasion and metastasis MMP2 
Limitless replicative potential CDK2, CDK4 
Telomerase 
Sustained angiogenesis VEGFR2 
HIF-1α 
 
Thus, for example, when GF receptors, overexpressed in many cancers, often 
carry tyrosine kinase activities in their cytoplasmic domains, many of these are client 
proteins of the molecular chaperone, Hsp90, involved in their assembly, stability and 
degradation [11, 19]. Increased activity of these kinases, because of overexpression 
or activating mutations, is strongly correlated with cancer progression. In particular, 
the cell surface tyrosine kinase ErbB2 has confirmed role in tumorigenesis. In animal 
mode, overexpression of this protein (~30% in breast and prostate cancer) was 
observed in specific tissues. The stability of the ErbB2 protein is inherently 
dependent on Hsp90, and inhibition of Hsp90 causes a dramatic decrease in ErbB2 
protein level, both in cultured cells and in animal tumor model. 
Moreover, in the acquired insensitivity in growth signals, when the function of 
E2F transcription factors is altered by phosphorylation by activated cyclin-dependent 
kinase 4 (CDK4), retinoblastoma protein is inactivated and its inhibition of E2F is 
relaxed, enabling the cell to traverse the cell cycle. CDK4 is a client protein of 
Hsp90, and Hsp90 inhibitors induce degradation of CDK4 [20]. Hence, inhibition of 
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Hsp90 fuction is expected not only to block cancer cells from entering the cell cycle, 
but also to block their progress through that cycle. 
In the case of tumor dissemination, as well, although Hsp90 is an intracellular 
chaperone, it has recently been found at cell membrane of highly metastatic cancer 
cells. A more recent study has shown the Hsp90 involvement in maturation of the 
cell surface enzyme matrix metallopreinase, in fact it was found to form a complex 
with cell surface Hsp90, therefore the chaperone is required for cancer invasion and 
metastasis [21]. 
When the limitless replicative potential is concerned, both the assembly of 
telomerase and the enzymatic activity to permit unlimited chromosomal replication, 
require the fuction of Hsp90 [22]. Thus, its inhibition significantly decreases 
telomerase activity, reverses the inhibition of telomerase shortening, and limits the 
replication potential of cancer cells. 
 
2.1. Hsp90: more than a Folding Tool 
 
Hsp90 is a highly conserved and essential stress protein, expressed throughout the 
eukaryotic lineage. Higher eukaryotes possess multiple Hsp90 homologues, 
including the highly conserved Hsp90-α and Hsp90-β isoforms (86% amino acid 
conservation) which are mainly cytoplasmic, GRP94 in the endoplasmic reticulum, 
and TRAP1 in the mitochondrial matrix. Although the Hsp90 bacterial homolog 
HtpG is typically nonessential, eukaryotes require a functional cytoplasmic Hsp90 
for survival under all conditions tested. Indeed whereas the term ‗heat shock protein‘ 
is perfectly appropriate for other HSPs, it is really somewhat of a misnomer for 
Hsp90. Hsp90, like many of HSPs, exerts its molecular chaperone activity by 
conformational cycles of binding and release which are dependent upon its ATPase 
activity [23,24] (Fig. 5). 
This ATP-driven conformational cycle is regulated by specific co-chaperones, 
such as Hsp70, Hop, immunophilins, cdc37 and p23, that complex with Hsp90 and 
assemble into the Hsp90 chaperone machinery, in order to assist the loading and 
release of client proteins (Fig. 6). 
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Figure 5. Nucleotide-dependent cycling of the Hsp90-based super-chaperone 
machine. Hsp90 forms the basis of a super-chaperone machine that promotes the proper folding of 
client proteins so that they can respond to a stimulus or bind ligand. However, the machine is in 
constant flux and cycles between two Hsp90 conformations, determined by nucleotide binding, which 
in turn specify which set of cochaperones associate with the chaperone complex. Cochaperones that 
can associate with one conformation or the other include p23, p50Cdc37, p60Hop, immunophilins, 
cyclophilins, Hsp70, Hip, phosphatase PP5, Hsp40, and BAG-1. Cycling of this machine is driven by 
ATP hydrolysis. Although Hsp90 is a weak ATPase, its activity is regulated by cochaperones and 
dramatically enhanced by client protein binding. A client protein’s half-life may be stochastically 
determined by the length of time it resides in association with the Hsp90-Hsp70 form of the chaperone 
machine, because at this time, the client protein is susceptible to ubiquitination and delivery to the 
proteasome. 
 
Figure 6. Model for tumor selectivity of Hsp90 inhibitors and Hsp90-dependent 
malignant progression. Hsp90 in normal cells exists in an uncomplexed form that has low affinity 
for Hsp90 inhibitor drugs, which accumulate poorly in normal tissues, and normal cells exhibit poor 
drug sensitivity. By contrast, the Hsp90 in cancer cells is involved in the active chaperoning of 
overexpressed oncoproteins and exists in a complexed form with co-chaperone proteins (p23 and Hop 
are not in the same complex). Complexed Hsp90 in cancer cells exhibits high-affinity binding to 
Hsp90 inhibitor drugs, which accumulate in tumor tissues, and tumor cells exhibit good drug 
sensitivity. This model predicts that the accumulation of mutant proteins in advanced cancer would 
further increase Hsp90 usage and make tumor cells more Hsp90 dependent. Furthermore, this model 
suggests that the high-affinity change of Hsp90 can be driven by the overexpression of oncoproteins, 
as well as by stressful conditions in normal cells (e.g. heat). 
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These key-components of the cell‘s signaling machinery are often activated, 
mutated and/or over-expressed in cancer cells and are considered responsible for the 
acquisition of the malignant phenotype. Subsequently, Hsp90 is viewed as a key 
player in the subversion of normal cells towards transformation and therefore an 
exciting new target for the development of innovating molecular cancer therapeutics. 
 
2.2. Hsp90: the Cancer Chaperone 
 
Hsp90, playing a pivotal role in the acquisition and maintenance of the malignant 
phenotype, is expressed in malignant cells from 2- to 10- fold higher than in normal 
cells [25]. These higher expression levels are coupled to multiple fundamental 
oncogenic pathways and indicate a crucial role associated with the development and 
maintenance of the malignant phenotype as well as the acquisition of drug resistant 
phenotypes. The abundance of Hsp90 in tumors in part reflects an appropriate cyto-
protective stress response to the hostile hypoxic, acidotic and nutrient-deprived 
tumor microenvironment. Consequently, the increased activities of this molecular 
chaperone allow  tumor cells to cope and adapt to environmental changes as well as 
to the imbalanced signaling, associated with neoplastic transformation, and thereby 
to escape apoptosis [26]. Malignant transformation involves the over-expression 
and/or mutation of multiple Hsp90-dependent key-regulators of cellular growth. 
Almost 50 proteins known to play important roles in the control of cell cycle and 
growth, including receptor protein kinases and transcription factors have been 
identified as oncogenic clients of Hsp90. It is indispensable for maintaining these 
proteins in an active conformation, and thereby it is considered to drive the cell to 
self-sufficiency in growth signals. Moreover, Hsp90 confers survival advantages to 
cancer cells through its association with important elements of apoptosis such as the 
Akt-survival pathway and the Raf/MAPK growth regulatory pathway. Finally, Hsp90 
plays important anti-apoptotic roles by interfering with the intrinsic caspase 
apoptotic pathway. In addition to permitting autonomous growth and facilitating cell 
survival with respect to stressful environmental challenges, Hsp90 also allows tumor 
cells to tolerate genetic alterations, including mutations of critical signaling 
molecules that would otherwise be lethal. It not only moderates the impact of 
potentially lethal mutations in cancer cells, but also stabilizes and permits the 
accumulation of mutant proteins, therefore functioning as a capacitor of evolution. 
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Thus, Hsp90 might also serve as a biochemical buffer for the genetic instability 
frequently found in cancers. As a result of this capacity, phenotypic diversity within 
the  tumor cell population increases and the evolution of invasive, metastatic and 
drug resistant phenotypes accelerates. To summarize, one can say that Hsp90 
participates in almost all the key processes of oncogenesis, such as self-sufficiency in 
growth signals and stabilization of mutant proteins. The involvement of this 
molecular chaperone in the acquisition and maintainance of the transformed 
phenotype is particularly interesting and suggests that inhibiting Hsp90 may have a 
coordinated effect on all of the key alterations on which cancer cells depend for their 
growth and survival. Consequently it is no wonder that Hsp90 has emerged as a 
promising and exciting target for the development of cancer therapeutics. 
 
2.2.1. Process of Carcinogenesis  
The ability of a tumor to induce the formation of a tumor vasculature has been 
termed the ―angiogenic switch‖ and can occur at different stages of the tumor 
progression pathway depending on the type of tumor and the environment [27]. 
Acquisition of the angiogenic phenotype can result from genetic changes or local 
environmental changes that lead to the activation endothelial cells (ECs). One way 
for a tumor to activate ECs is through the secretion of proangiogenic growth factors, 
which then bind to receptors on nearby latent ECs that line the interior of vessels, 
leading to vasodilatation and increase in vessel permeability. The ECs migrate and 
proliferate to form new branches from the pre-existing vasculature by detaching from 
the extracellular matrix and basement membrane (Fig. 7). 
 
Figure 7. Tumor cells secrete proangiogenic growth factors. PI3K indicates 
phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; HIF-1, hypoxia inducible 
factor-1; VEGF, vascular endothelial growth factor. 
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The proangiogenic growth factors may be overexpressed because of genetic 
alterations of oncogenes and tumor suppressors, or in response to the reduced 
availability of oxygen. Tumor cell expression of many of the angiogenic factors, 
including vascular endothelial growth factor (VEGF), is regulated by hypoxia 
through the transcription factor hypoxia inducible factor (HIF) [28]. As the tumor 
cells proliferate, oxygen becomes depleted and a hypoxic microenvironment occurs 
within the tumor. HIF is degraded in the presence of oxygen, and therefore formation 
of hypoxic conditions leads to HIF activation and transcription of target genes (Fig. 
8). The strongest activation of HIF results from hypoxia, but several other factors can 
contribute to the increased expression and activity of HIF, including growth factors 
and cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), 
epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1), which lead 
to increased cell signaling. Along similar lines, oncogenes that trigger increased 
expression of growth factors and overactive signaling pathways can increase HIF 
expression and activity. For example, mutant Ras can contribute to tumor 
angiogenesis by enhancing the expression of VEGF through increased HIF activity. 
The oncogenes v-Src and HER2, PI3K and MAPK signaling pathways have also 
been shown to up-regulate HIF expression and HIF transcriptional activity. 
 
Figure 8. Examples of inhibitors known to act on hypoxia inducible factor and/or 
HIF regulatory pathways. 2ME2, 2-methoxyestradiol; HRE, hypoxia response element. 
 
2.2.2. HIF: Pathways and Binding Partners 
HIF is a transcription factor involved in cellular adaptation to hypoxia. HIF 
transcriptional activity is regulated by the presence of oxygen and becomes active in 
low oxygen conditions (hypoxia). It controls a large number of genes involved in 
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angiogenesis. The active HIF complex is comprised of an α and β subunit, in addition 
to coactivators including p300 and CREB binding protein (CBP). The HIF-β subunit 
(also known as ARNT) is a constitutive nuclear protein with additional roles in 
transcription not associated with HIF-α. In contrast to HIF-β, the levels of the HIF-α 
subunits and their transcriptional activity are regulated by oxygen availability. There 
are three related forms of human HIF-α (HIF-1α, HIF-2α, and HIF-3α), each of 
which is encoded by a distinct genetic locus. HIF-1α and HIF-2α have been the best 
characterized, possessing similar domain structures that are regulated in a related 
manner by oxygen, although each isoform has distinct and separate roles. The role of 
HIF-3α is not fully understood, although a truncated form of murine HIF-3α, known 
as inhibitory Per/Arnt/Sim (PAS) domain protein (IPAS), has been found to act as an 
inhibitor of HIF via dimerization with HIF-β. Both the HIF-α and HIF-β subunits are 
produced constitutively, but in normoxia HIF-1α and HIF-2α are degraded by the 
proteasome in an oxygen-dependent manner. Hydroxylation of two prolines in HIF-α 
enables the protein to bind to the von Hippel-Lindau tumor suppressor protein 
(pVHL), which links HIF-α to a ubiquitin ligase complex. This ligase catalyzes 
polyubiquitinylation of HIF-α, targeting it for degradation by the proteasome. In 
addition, hydroxylation of an asparagine residue in HIF-α disrupts the interaction 
between HIF-α and the coactivator p300, through a process independent of 
proteasomal degradation, which leads to reduced HIF transcriptional activity. In this 
manner, asparaginyl hydroxylation acts as a regulatory switch controlling the activity 
and specificity of HIF gene expression, as opposed to the prolyl hydroxylations, 
which control HIF-α stability. In hypoxia, minimal to no hydroxylation occurs, 
enabling HIF-α to avoid proteasomal degradation and to dimerize with HIF-β and 
coactivators, forming the active transcription complex on the hypoxia response 
element (HRE) associated with HIF target genes (Fig. 9). 
Because HIF regulates genes that enable cell survival in a hypoxic 
environment, including those involved in glycolysis, angiogenesis, and expression of 
growth factors, it has significance in the biology and regulation of tumor growth. 
The central role of HIF in the activation of angiogenic-related genes makes it a 
promising target for the treatment of solid tumors, particularly because HIF-1α 
and/or HIF-2α are reported to be overexpressed in the majority of solid tumors. 
HIF-1α (and occasionally HIF-2α) overexpression in tumors has been found to be 
positively correlated with angiogenesis, aggressiveness, metastasis, and resistance to 
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radiation/chemotherapy and negatively correlated with disease progression, survival, 
and outcome. 
 
 
Figure 9. HIF-α and HIF-β subunits are both produced constitutively in normoxia 
and in hypoxia 
 
Downstream from HIF-1α, several factors regulate the proliferation and 
mobility of target vascular endothelial cells and at least two of these, VEGF and 
nitric oxide synthase, require Hsp90 or their induction and stability in vascular 
endothelial cells. Also HIF is regulated at the level of protein stability, and increased 
amount of Hsp90 is needed to mediate its stabilization and accumulation. HIF 
interacts with Hsp90 [29] and both geldanamycin (GA) and radicicol (the first 
discovered inhibitors, see below) reduce HIF-dependent transcriptional activity 
[9,30,31]. Hur et al. demonstrated that HIF from radicicol treated cells was unable to 
bind DNA [30], suggesting that Hsp90 is necessary for mediating the proper 
conformation of HIF and/or recruiting additional cofactors [32]. Additionally, GA 
downregulates HIF expression by stimulating the protein‘s VHL-independent 
proteasomal degradation [31]. 
 
2.2.3. Hsp90 Inhibitors: Targeting Signal Transduction in Cancer 
The earliest inhibitor of Hsp90 was the natural product geldanamycin which is 
a member of the family of ansamycin antibiotics. This agent has featured in the 
literature for several years as an antitumor agent, and was originally isolated based 
on its ability to promote a significant decrease in the activity of oncogenic tyrosine 
kinases such as v-Src and ErbB-2. In 1994, Whitesell et al. [33] reported that 
ansamycins, and GA in particular, exerts its function by acting as a nucleotide 
mimetic and by binding specifically to the ATPase domain of Hsp90. This action 
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results in inhibition of its chaperone function, and consequently in the ubiquitination 
and degradation of client proteins by the proteasome pathway. Despite their 
promising activity as anticancer agents, these antibiotics proved to have limited 
clinical potential, because of their high liver toxicity and/or cellular instability. 
However, subsequent derivatization of GA yielded analogues with reduced liver 
toxicity, that however retained the potent antitumor activity of the parent compound. 
One such example is the analogue 17-allylamino-17-demethoxygeldanamycin 
(17AAG) which has already entered clinical trials [34-36]. 
 
Table 3. Hsp90 inhibitors 
Name Chemical Class Binding Site 
GA Benzoquinone ansamycin N-terminal ATP-binding pocket 
17-AAG GA-derivative N-terminal ATP-binding pocket 
17-DMAG GA-derivative N-terminal ATP-binding pocket 
Radicicol Macrolide N-terminal ATP-binding pocket 
PU24FC1 Purine scaffold N-terminal ATP-binding pocket 
CCT018159 Pyrazole N-terminal ATP-binding pocket 
Radamycin Hybrid N-terminal ATP-binding pocket 
Novobiocin Noviosylcoumarin crosslinker C-terminus 
 
At present, several derivatives of natural products or fully synthetic small-
molecule drugs that target Hsp90 have been discovered as potential anticancer agents 
(Table 3, Fig. 10). These drugs are considered as unique in that, although they are 
directed against a specific molecular target, they simultaneously inhibit multiple 
signaling pathways by inactivating, destabilizing, and eventually leading to 
degradation of numerous chaperone dependent client proteins. As a consequence 
they are competent to mount a multi-pronged assault on cancer cells. Moreover, 
although initially there were concerns that Hsp90 targeted drugs would attack 
proteins expressed both in normal and malignant cells, and thus would lack 
specificity and cause damage to normal tissues, these fears were proved unfounded. 
Interestingly, exclusively  tumor cells were shown to exhibit sensitivity to Hsp90 
inhibition, thus lending credence to the feasibility of selectively targeting cancer 
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tissues via the pharmacological modulation of Hsp90 function [37,38]. Even more 
remarkably, Hsp90 inhibitors sensitize  tumor cells to the cytotoxic effects of a 
variety of standard therapeutic agents.  
 
 
Figure 10. Structure of Hsp90 inhibitors 
 
Consequently they are likely to have broad utility in combination therapy. At 
present, structurally unique Hsp90 inhibitors are undergoing preclinical and clinical 
evaluation. These anti-Hsp90 drugs show great promise through their potential to 
block a wide spectrum of the main pathways of autonomous tumor growth. 
 
2.3. Extracellular Hsp90: Chaperoning Immune Response and Cell Invasion 
 
While Hsp90 was originally discovered and perceived as an intracellular molecular 
chaperone, more than two decades later, a number of studies challenged this view. In 
1986, Ullrich et al. identified Hsp90 as a tumor-specific antigen localized on the 
surface of mouse cells [39]. Since then, several researchers have reported the 
presence of this molecular chaperone on the cell surface. However these studies did 
not attribute precise functions to this pool of the molecule and the best studied cases 
of extracellular Hsp90 concerned innate and adaptive immunity. More specifically, 
Radamycin 
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Hsp90 has been documented as a key player in antigen processing and presentation 
during immune responses, where it was reported to play crucial roles in antitumor 
and antiviral responses through interaction with various HSP receptors on APCs, 
such as CD40, CD91 and TLR4 [40,41]. 
 
Figure 11. Summarised list of the extracellular and intracellular Hsp90-interacting 
molecules 
 
Different independent studies are in agreement and strongly indicate that 
extracellular Hsp90 is involved in the molecular pathways leading to cell motility, 
invasion and cancer cell metastasis. As shown in Fig.11, while more than 100 
intracellular Hsp90 interacting proteins have been reported, a relatively small number 
of surface molecules have been identified so far to interact with the extracellular pool 
of Hsp90. However, the above mentioned studies demonstrate that the presence of 
Hsp90 on the cell surface is a wide-ranging phenomenon suggesting that this 
extracellular pool of the molecule performs ―extra-ordinary‖ chaperoning activities 
to a number of surface molecules similarly to its intracellular counterpart. This 
scenario is confirmed by accumulating data reporting that several components of the 
Hsp90 chaperone machinery, such as Hsp70, Hop, p23 and cdc37 are also present on 
the cell surface. On the other hand, it was suggested that surface Hsp90 participates 
in cancer cell invasion through the signaling processes involved in the regulation of 
focal adhesion formation and cell migration, a complex and multistep process, based 
on a multitude of cellular and molecular mechanisms (Fig. 12). 
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Figure 12. Schematic representation of 4 proposed models concerning the 
involvement of extracellular Hsp90 in cell migration and invasion. 
A. Hsp90 is identified extracellularly, in association with MMP2 and this interaction is 
suggested to be necessary for the maturation of the enzyme, which in turn is crucial for 
fibrosarcoma cell invasion. 
B. Surface Hsp90 is shown to participate in melanoma and prostate cancer cell invasion 
through regulation of focal adhesion formation, including ECM-induced c-src/integrin 
association and re-organization of the actin cytoskeleton. 
C. Surface Hsp90 is shown to be involved in breast cancer cell invasion, stimulated by the 
presence of HRG. The model suggests that Hsp90 exerts its function through an interaction 
with the extracellular domain of ErbB2, essential for the activation of the downstream signal 
transduction pathways leading to actin cytoskeletal re-arrangement and cell invasion. 
D. TGFa is shown to trigger keratinocytes to secrete Hsp90 in the culture medium through 
the exosome pathway. 
 
The basic steps include the coordinated assembly and dis-assembly of 
adhesions and the reorganization of the actin cytoskeleton in order to generate 
productive movement. Molecules from the environment, including chemoattractants, 
growth factors and extracellular matrix proteins, regulate cell polarization through 
the spatially controlled recruitment of signaling complexes that modulate the actin 
cytoskeleton and mediate the extension of membrane protrusions at the leading edge. 
Finally several molecules have been described as being tightly involved in the re-
organization of the actin cytoskeleton of a cell. These include among others adhesion 
molecules, like integrins and selectins, transmembrane receptor tyrosine kinases 
(EGF-R, ErbB-2), phospholipids, focal adhesion kinases (FAKs) and GTPases. 
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3. AIM OF THE WORK 
 
The discovery of Hsp90 on the surface of cancer cells, in combination with 
accumulating evidence reporting its involvement in invasion and metastasis 
commences a new and exciting era in the field of cancer therapeutics [42]. Cell 
surface and intracellular Hsp90 provides a novel and promising molecular target for 
the development of effective antimetastatic drugs. Although compounds targeting 
Hsp90 already exist, the need for further development of Hsp90 inhibitors is 
emerging.  
Therefore, due to the interest on Hsp90 as biological target in the search of 
anticancer drugs, the first part of my PhD research work was devoted to the design of 
new polyheterocycle derivatives as potential Hsp90 inhibitors.  
These were identified by molecular modeling studies and then optimized 
through the introduction of appropriate substituents. The new potential inhibitors 
were prepared by using the suitable synthetic methodologies. The selected 
compounds were tested in biological screening to investigate their activity as 
antiproliferative compounds, but also in particular for their specific effect towards 
protein targets such as Hsp90 and transcriptional factor HIF-1. 
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4. RESULTS AND DISCUSSION 
 
4.1. Leads Identification 
 
In the last decade the application of computational methodologies in all the 
medicinal chemistry fields has found an amazing development. All these efforts were 
focused on the searching of new leads possessing a specific bio-molecular target 
affinity. Thus, different molecular modeling approaches were used in simulation of 
molecular behaviour for a specific biological target. 
During my PhD experimental work the in silico approach, in the search of 
new Hsp90 inhibitors, was performed by using two different points of views. The 
first, called the multivariate protocol, consists in the application of a chemiometric 
methodology [43] on an “in house” ligands-descriptors matrix database. The second 
deals with the well known pharmacophore based virtual screening on a large 
database. However, both approaches require preliminary a deep knowledge and 
analysis of the structure of the biological target. By crystallographic studies it was 
possible to characterize the individual domains and the structure for ATP-bound 
conformation of the intact dimeric chaperone. 
 
4.1.1. Structure of Hsp90 
Crystallization of a full-length Hsp90 was ﬁrst reported nearly 10 years ago. 
However, well-ordered diffraction-quality crystals capable of yielding an atomic 
resolution structure remain elusive, although some progress is being made [10]. An 
enormous amount has been learned from structural studies of domains and large 
subconstructs, so that atomic structures for almost all segments of the Hsp90 
structure are now known (Fig. 13). 
 
Figure 13. Schematic of the domain structure of yeast Hsp90  
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4.1.1a N-Terminal Domain—Nucleotide and Drug Binding 
The first breakthrough into Hsp90 structure came from the identification of an 
N-terminal ~25kDa domain, which was readly released from the protein by limited 
proteolysis. Crystal structures of this domain, from human and yeast Hsp90s revealed 
a two-layer α/β sandwich structure in which the helices delimit a pocket extending 
from the surface to the buried face of the highly twisted antiparallel β-sheet [10, 44]. 
In the human structure, this pocket was found to be the binding site for the 
macrocyclic antitumor agent geldanamycin [45], whose binding to Hsp90 had been 
shown to disrupt productive complexes with protein kinase and steroid hormone 
receptor clients. In the absence of any mechanistic model for Hsp90 function at the 
time, inhibition by geldanamycin was erroneously attributed to competitive blockade 
by the macrocycle of a putative binding site for an unfolded client protein [46]. A 
cocrystal structure of the yeast Hsp90 N terminus and ATP/ADP revealed the N-
terminal pocket as the binding site for adenine nucleotides, identifying key conserved 
functional residues and explaining the action of geldanamycin and related 
compounds as competitive inhibitors of ATP binding (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  
(a) Crystal structure of the 
N-domain of yeast Hsp90, 
showing the binding site for 
ATP/ADP. The protein is shown 
as a secondary structure cartoon 
rainbow (blue-red) from the N to 
the C terminus of the construct.  
(b) Comparison of co-crystal 
structures of yeast Hsp90 
N-domain and bound ADP, with 
complexes of the antibiotics GA 
and radicicol.  
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Involvement of ATP in Hsp90 function had been suggested several years 
earlier, but it was associated with apparent autophosphorylation, suggesting 
contamination with protein kinases, although subsequent biochemical analysis 
seemed to show conclusively that Hsp90 lacked signiﬁcant ADP/ATP afﬁnity. With 
the realization that geldanamycin was a highly speciﬁc competitive inhibitor of ATP 
binding to Hsp90 [47], it became possible to measure the low inherent ATPase of 
Hsp90s accurately, without interference by contamination kinases or other more 
active ATPases. The identiﬁcation of key residues in the N-terminal structure made it 
possible to demonstrate unequivocally, by mutagenesis in engineered yeast strains, 
that the biological function of Hsp90 was absolutely dependent on its ability to both 
bind and hydrolyze ATP. 
 
4.1.1b Middle Segment—Client Protein Binding and Catalytic Loop 
Following from structural analysis of the yeast and human N-terminal domains, 
the crystal structure of a proteolytically resistant middle segment from yeast Hsp90 
was determined (Fig. 15a). This structure consists of a large α-β-α domain at the N-
terminus of the construct connecting to a small α-β-α domain at the C-terminus via a 
series of short α-helices in a tight coil [48]. The middle segment is a major site for 
client protein interactions, with a conserved hydrophobic patch centered on Trp 300 
and an unusual amphipathic protrusion formed by residues 327–340, with one 
exposed hydrophobic side and one positively charged side, being particularly 
important (Fig. 15b).  
 
 
 
Figure 15.  
(a) Crystal structure of the 
middle segment of yeast 
Hsp90, showing the three 
subdomains. 
(b) As in (a) but rotated 
~90 around the vertical, 
with the hydrophobic 
residue implicated in 
client protein binding 
(green) and the catalytic 
loop bearing the essential 
residue Arg 380 (red). 
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Again by analogy with other GHKL proteins, it was anticipated that the middle 
segment also contributed a key catalytic lysine residue that would interact with the γ-
phosphate of an ATP molecule bound in the N-terminal domain. Instead, a conserved 
arginine, Arg 380, was found by mutagenesis to be essential for ATPase activity in 
vitro and for the essential functions of Hsp90 in yeast in vivo, suggesting that it plays 
the same role of polarizing the β-γ phosphodiester bond. However, at least in the 
isolated Hsp90 middle segment, this connecting loop is highly structured with Arg 
380 involved in a short α-helix, so that substantial remodeling of this segment would 
be required for Arg 380 to fulﬁll its catalytic role. 
 
4.1.1c. C-Terminal Domain—Dimerization 
More recently the structure of the C-terminal domain from the E. coli Hsp90 
homologue HtpG has been determined (Fig. 16). Consistent with previous 
biochemical observations that the C-terminal domain is essential for Hsp90 
dimerization, the HtpG C-terminal structure is a dimer of a small mixed α/β domain 
[49]. The dimer interface is formed by a pair of helices at the C-terminal end of the 
domain packing together to create a four-helix bundle. Nonetheless, the C-terminal 
domains in eukaryotic and bacterial Hsp90 is important for the recruitment of other 
cochaperones, which form the superchaperone complex with Hsp90. 
 
Figure 16. Crystal structure of the dimeric C-terminal domain of the E. coli Hsp90 
homologue, HtpG (left) and viewed down the local pseudotwofold symmetry axis (right). 
This region corresponds to residues 549–674 of the yeast protein and lacks the extreme C-
terminus of ∼30 residues that provides the binding site for TPR domain cochaperones in 
eukaryotic Hsp90s. 
 
4.1.2. Multivariate Protocol 
In this in silico approach, the selection of suitable compounds was performed 
on the “in house” database of structures incorporating pyrimidine core structure of 
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type 1-15 (Fig. 17). The designed derivatives are all synthesizable through well 
known and optimized experimental procedures, developed by the research group I 
worked with. [50-53].  
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Figure 17. Structures included in the “in house” database 
 
Initially we started by choosing 48 heterogeneous biological targets (Table 4), 
including Hsp90, for which it is known a consistent set of inhibitors with activity or 
binding affinity available data, resulting a total of 7490 molecular structures, 138 of 
which are known inhibitors of Hsp90. 
The molecular structures were downloaded from binding DataBase [54], a 
public available database of measured binding affinities, focused on the interaction 
between proteins considered to be drug targets with small drug-like molecules. These 
structures were used as input data for CODESSA PRO program [55], where 
calculation of molecular descriptors was carried out. CODESSA PRO 
(COmprehensive DEscriptors for Structural and Statistical Analysis) is a multi-
purpose program providing various methods for statistical analysis of experimental 
data such as Partial Least Squares, (Multiple) Linear and Non-Linear Regressions, 
and Principal Components Regression. A set of 615 molecular descriptors derived 
from geometrical and quantum-chemical structures was computed in our study, as 
available in the program. All descriptors were divided into five groups: 
constitutional, topological, geometric, electrostatic, and quantum-chemical. 
Constitutional descriptors reflect only the molecular composition of the compounds 
as the number of atoms, the number of bonds and the molecular weight, and so on. 
Topological descriptors describe the atomic connectivity in a molecule. Geometric 
descriptors are calculated from the three-dimension atomic coordinates of the 
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molecule, and comprise moments of inertia, shadow indices, molecular volume, and 
molecular surface area-like descriptors. 
 
Table 4. Biological targets and number of inhibitors 
Target names (bindingDB ID)  
11-beta-Hydroxysteroid Dehydrogenase (11betaHSD1) 40 
ABL Kinase (ABL) 70 
Adenosine receptor A1 (ARA1) 110 
Aldose Reductase (ALR2) 126 
Aldosterone Synthase (CYP11B2) 129 
Androgen Receptor (AR) 244 
Angiotensin Converting Enzyme (ACE) 51 
Angiotensin Converting Enzyme 2 (ACE2) 73 
Anthrax lethal factor (ALF) 130 
Aromatase (AROM) 440 
Asparaginyl Endopeptidase (AE) 27 
Aurora Kinase A (Aurora-A) 179 
BCL-2 (BCL-2) 31 
BCL-xl (BCL-xl) 50 
Ca-Moduline kinase 2 (CaMK2) 20 
Cannabinoid Receptor 2 (CannRec2) 104 
Carbonic Anhydrase 1 (CA-1) 305 
Carbonic Anhydrase 2 (CA-2) 402 
Carbonic Anhydrase 4 (CA-4) 203 
Caspase-1 (CSP1) 83 
Caspase-3 (CSP3) 226 
Checkpoint kinase (ChK1) 57 
Chymotrypsin (CT) 33 
Collagenase (CLG) 309 
Corticotropin Releasing Factor Rec 1 (CRFR1) 62 
Cyclin-Dependent kinase (CDK4) 631 
Delta Opioid Receptor (DOR) 25 
DiacylGlycerolAcylTransferase (DGAT-1) 14 
Dihydrofolate Reductase (DHFR) 144 
Dopamine Transporter (DAT) 58 
EGF-R Tyrosin Kinase (EGF-R TK) 979 
ERK-2 Kinase (ERK-2) 66 
Estrogen Receptor (ER-alpha) 199 
Factor Xa (Fxa) 109 
Ghrelin Receptor  (GHR) 90 
Glucocorticoid Receptor (GR) 109 
Glutaminyl Cyclase (GC) 183 
Glycogen Synthase Kinase 3α (GSK3α) 229 
Heat Shock Protein 90 (HSP90) 138 
Histone Deacetilase 1 (HD1) 143 
Matrix MetalloProteinase 13 (MMP-13) 142 
Matrix MetalloProteinase 3 (MMP-3) 80 
Neutrophil EndoPeptidase (NEP) 26 
PDK1 Kinase (PDK1) 97 
PhosphoDiEsterase Type 10A (PDE10A) 41 
Plasmepsin 1 (PSP1) 51 
Protein Tyrosin Phosphatase (PTP1B) 336 
Tyrosin Kinase C-kit (TKC-kit) 96 
 7490 
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Electrostatic descriptors reflect characteristics of the charge distribution in the 
molecule, calculated by the Zefirov method. Quantum-chemical descriptors add 
important information to the conventional descriptors. They are divided into three 
subgroups: charge distribution-related, valence-related and quantum mechanical 
energy-related descriptors. 
Among the whole set of calculated properties a total of 173 descriptors (not 
correlated) were selected. Therefore the resulting matrix, 7490 rows (structures) 
versus 173 columns (descriptors), was submitted to Principal Component Analysis 
(PCA). PCA is one of the most-widely used multivariate exploratory techniques [56]. 
Principal Components are able to detect internal relations between characteristics of 
a set of objects, thus enabling a drastic reduction of the dimensionality of the original 
raw data. This reduction is achieved by transforming the original matrix to a new 
one, whose set of variables, termed as Principal Components (PCs), appear to be 
orthogonal to each other (uncorrelated) and ordered so that the first few, with 
descending importance, retains most of the variance content from the total set of 
original variables. 
In PCA, the initial data matrix D is represented as the inner product of two 
matrices (eq. 1): 
D = RC  (eq. 1) 
The row matrix R, named the score matrix, has the dimensionality r × n, where 
r is the number of observations (compounds in our case) in the initial data set, and n 
is the number of PCs. The column matrix C, named the loadings matrix, has the 
dimensionality n × c, where c is the number of observable properties (molecular 
descriptors in our case) in the initial data. 
PCA can be highly useful for data classification and pattern recognition. In the 
two-dimensional plotting of a score vector against another score vector, objects with 
similar properties are clustered. Moreover, in the two-dimensional plotting of a 
loading vector against another loading vector, the initial statistical properties 
reflected in those two score loadings are clustered together. The number of PCs 
(scores, loadings) existing in a characteristic vector space can be equal to, or less 
than, the number of variables in the data set. The first Principal Component is 
defined as that giving the largest contribution to the respective PCA of linear 
relationships exhibited in the data. The second component may be considered as the 
second best linear combination of variables that accounts for the maximum possible 
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of the residual variance after the effect of the first component is removed from the 
data; next components are defined until practically all the variance in the data is 
exhausted. For this study PCA was performed with STATISTICA 6.0 package. From 
the analysis of the significant components emerges that 68% of the variance is 
comprised in the first five components (Table 5). 
 
Table 5. Statistics of PCs 1-5 
 
In Fig. 18, the 2D representation (PC1 versus PC2) for all matrix compounds is 
reported. 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Projection of the cases on the factor-plane 
 
For each of 48 biological targets, the 5-dimensional barycentric coordinates 
were computed (in Fig. 19 the two-dimensional coordinates are reported). 
 
PCs Eigenvalue Cumulative Eingenvalue % Total % Cumulative 
1 61.30897 61.3090 35.43871 35.4387 
2 29.63579 90.9448 17.13052 52.5692 
3 11.02439 101.9692 6.37248 58.9417 
4 9.08724 111.0564 5.25274 64.1944 
5 6.10995 117.1664 3.53177 67.7262 
Projection of the cases on the factor-plane (  1 x   2)
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Figure 19. Scatter plot 
 
Each compound belonging to the “in house” database was projected in the 5-
dimentional biological space and the distances from all baricentric coordinates, 
related to each biological target, were calculated. These distances represent the 
scores affinity of all structures respect to 48 biological targets. This approach 
allowed to identify some derivatives of the tetracyclic system pyrido[3',2':4,5]thieno-
[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine 3 as good potential Hsp90 inhibitors. In fact, 
as shown in Fig. 20, the baricentric coordinates related to core 3 are those with the 
shorter distances and therefore with the higher Hsp90 affinity. 
Figure 20. Scatter plot 
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4.1.3. Pharmacophore Based Virtual Screening 
According to this approach the entire ZINC Database, a collection of over 5 
million purchasable and non-purchasable compounds, was used as starting point in a 
virtual screening on ATP site of the Hsp90. The molecular docking protocol, showed 
in figure 21, was build up.  
 
Figure 21. Virtual screening flowchart 
 
Preliminarily a first discrimination by means Lipinski‘s Rule of Five was 
applied. In the second step, the survival compounds were submitted to a two 
accuracy levels Molecular Docking Screening, using the software Glide [57]. The 
first level, termed High Throughput Virtual Screening (HTVS) allowed a rapid 
evaluation of the whole data set; the most highly ranked compounds (providing a 
GlideScore < -7) were further submitted to the Standard Precision (SP) molecular 
docking, which involved a more accurate algorithm for the evaluation of interactions. 
The top scored compounds (GlideScore < -7.5) were further discriminated 
using two set of pharmacophoric hypotheses, both built using as training set the 
Hsp90 inhibitors included in the binding DataBase. When our work started this 
database contained a total of 49 derivatives classified as Hsp90 inhibitors, belonging 
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to different structural classes including purines (12), pyrazoles (28), and 
sulfonamides (9) (Fig. 22).  
 
Figure 22. Structure of representative Hsp90 inhibitor of each class 
 
First, as described in the case of ZINC database, Molecular Docking 
experiments were carried out using Glide software, in order to obtain information on 
the conformations adopted by ligands at the active site of their molecular target. 
Analysis of  the results allowed to appreciate that each class of inhibitors shares a 
common binding mode (Fig. 23).  
 
 
Figure 23. Inhibitors binding modes: a: sulfonamides, b: pyrazoles, c: purines, d: 
interactions at the binding site. 
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Despite the differences occurring in the orientation of the substituents, the core 
structures (purine, pyrazole, or sulfonamide ring) are well superimposed for each 
class of derivatives. Moreover, the results evidenced the occurrence of several 
recurrent interactions with the active site, confirming the role of some key residues 
such as Asp51, Asp54, Lys58, Asp93, Gly97, Lys112, Phe138, Thr184, Thr 162, Val 
150 and Val 186, which provide direct hydrogen interactions, as also suggested by 
recent docking studies [58]. 
The first hypothesis (Hypo1), called Docking derived pharmacophore, 
performed by Phase software [59], was built using the frozen conformations obtained 
by the docking of all 49 compounds, in the N-terminal domain of  Hsp90 (PDB id: 
2BZ5). Therefore this is a receptor-based hypothesis, since the active site 
architecture influenced the training set conformations. Hypo1 consists of two H-bond 
acceptors regions located at 7.98 Å distance each other, and two ring-containing 
regions, located at 4.03 Å each other and at 3.46-2.78 Å from the two H-acceptors 
centers (Fig. 24). 
 
 
 
 
 
 
 
Figure 24. Docking derived pharmacofore 
 
The second hypothesis (Hypo2), called in vacuo derived pharmacophore, was 
built using the conformations obtained through an in vacuo conformational search 
involving the generation of a maximum of 10
3
 conformers for each compound of the 
training set. Thus, this is a structure-based hypothesis, since it only takes into 
account the structural diversity of the inhibitors, without considering the active site 
shape. Hypo2 consists of two H-acceptors regions placed at 7.89 Å each other, with 
two ring-containing regions placed at 4.65 Å each other and 2.80-2.56 Å from the 
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H-acceptors. An additional H-donors region is situated at 6.63-3.58 Å from the rings 
and at 4.79 Å from the H-acceptor region (Fig. 25). 
 
Figure 25. “In vacuo” derived pharmacofore 
By means this virtual screening approach it was possible to select 112 
derivatives included in the ZINC Database which resulted common to both 
pharmacophore hypotheses and provided a good docking score using both HTVS and 
SP accuracy levels. These compounds can constitute suitable leads for new Hsp90 
inhibitors. The selected structures can be classify into four main classes, quinazoline 
of type 16, pyrrolo-phthalazines of type 17, pyrazoles of type 18 and amino-
cyanopyrimidines of type 19 (Fig. 26). 
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Figure 26. Identified lead scaffolds 
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4.2. Synthetic Methodologies for the Selected Leads 
 
4.2.1. Annelated triazolopyrimidines 
According to the results of computational studies, compounds of type 3 (cfr 
Fig. 17) presenting the pyrido[3',2':4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine 
core structure, a tetracyclic system identified as potential Hsp90 inhibitor, were 
prepared. The synthetic access to this heterocyclic ring system could be provided by 
suitable domino reactions. The methodology was exhaustively investigated by our 
reasearch group [50,53,60]. In fact pyrido-thieno-triazolo-pyrimidine can be related 
to other class of flat heterocyclic structures of type 20 that, in turn, are similar to 
anticancer compounds known in literature, such as acridines, anthracyclines, and 
actinomycins (Fig. 27).  
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Figure 27 
 
In fact they present moieties suitable for the intercalation into DNA, being 
capable of interactions such as charge-transfer, as well as hydrogen bonding and 
electrostatic interactions. Moreover if they bear suitable side chain, further 
interactions of these ligands with the other important architectural feature of DNA, 
its minor groove, can be envisaged. In fact the core polycyclic nucleus can be 
functionalized at NH in 4 position by insertion of appropriate chain shape moieties of 
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variable length and with different physicochemical character, which can enhance the 
antitumor activity (Table 6). 
Table 6 
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The synthetic metodology always involved a domino reaction between an 
azidothienopyridine and substituted acetonitriles. In fact a domino reaction is a 
process involving two or more bond-forming transformations (usually C-C or C-N 
bonds), which takes place under the same reaction conditions without additional 
reagents and catalysts, and in which the subsequent reaction results as a consequence 
of the functionality formed in the previous step. The azido moiety acts as a 
1,3-dipolar reagent in cycloaddition reactions with dipolarophiles such as anions 
from methylene active derivatives. The intermediate resulting from the 
1,3-cycloaddition reaction is a 1-(2-carboxyethyl-heteroaryl)-2-aminotriazole, which 
presents an amino group able to give rise to the pyrimidine ring, being within 
reacting distance to the carboxylate function. 
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The starting 3-aminothienopyridine 23 was obtained from commercially 
available 2-chloro-3-cyanopyridine and ethyl thioglycolate as described in literature 
[61] (Scheme 1).  
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It was diazotized with sodium nitrite and in situ addition of sodium azide, in 
acetic acid at 0°C or in concentrated solforic acid according to the classical method 
used for the preparation of azides. But, in our case it was impossible to isolate the 
desidered compound. However azide 24 was suitably isolated, in good yields, using 
6N hydrochloric acid  and cooling to -10°C (Scheme 2). 
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The azide 24 was added at room temperature to the sodium salt of acetonitriles 
25 in absolute ethanol. After 24 hours, the TLC analysis showed mainly a new 
compound, that was purified by column chromatography using 
dichloromethane/methanol 9:1 as eluant (Scheme 3).  
The structures of 27a,b were confirmed by spectroscopic data, in particular by 
the presence in the IR spectra of the typical absorption bands (at 3405-3368 and 
1685-1630 cm
-1
) due to the presence of a cyclic-amide structure. Moreover, in the 
13
C NMR the diagnostic signal of the amide carbonyl moiety was found in the range 
162.3-160.7 ppm. 
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A particular behaviour was observed in the reaction of azidothienopyridine 
with malonitrile. In this case, it was possible to isolate the intermediate 3-(triazol-1-
yl) compound 26a with the amino group and carboxylate function unreacted. The 
cyclization originating the pyrimidine ring and the yield of the reaction are 
influenced by the amount of the solvent, in fact a smaller volume of the solvent 
allows to isolate the compound of type 26. Moreover, the isolation of the 
intermediate confirmed the mechanism of these reactions. 
As already found in the case of pyrrolo[3,4-e][1,2,3]triazolo[1,5-a]pyrimidine 
derivatives which rearranged to pyrrolo[3,4-d][1,2,3]triazolo[1,5-a]pyrimidines [50], 
and of pyrazolo[3,4-e][1,2,3]triazolo[1,5-a]pyrimidine converted into pyrazolo[3,4-
d][1,2,3]triazolo[1,5-a]pyrimidine [51], compound 27b heated under reflux in basic 
condition and aqueous DMSO can give rise to the linear isomer 28 (Scheme 4).  
Molecular Modeling studies and biological screening on series of isosters 
evidenced that derivatives of polycyclic systems, such as pyrido[3‘,2‘:4,5]thieno[2,3-
e][1,2,3]triazolo[1,5-a]pyrimidin-6(5H)-one, can modify their elettronic and steric 
feature, physicochemical character and permeability through the cell membrane, by 
the introduction of side chain moieties in the 4 position of the ring. Therefore the 
synthesis of such compounds was performed. 
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Derivative 29 and the corresponding linear isomer 32 were first obtained from 
the sodium salt of 27b, generated in situ by using sodium hydride, and ethyl 4-
bromobutyrate in absolute DMF at 80°C, but in low yield (Scheme 5). In this case, 
even if water is not present in the reaction environment, the Dimroth rearrangement 
is facilitated by the presence of lipophilic side chain in lactamic nitrogen position. 
The use of potassium carbonate (3-fold excess of the starting material), in absolute 
DMF, increased the yields of 29 to 63% and 32 to 11%. Subsequent hydrolysis with 
NaOH in EtOH/H2O, at room temperature for the angular derivative 29 and under 
reflux for the linear isomer 32, quantitatively yielded the corresponding carboxylic 
acids 30 and 33. 
The reaction leading to the amide derivative 31 was first carried out using 
histamine in presence of dicyclohexylcarbodiimide (DCC) as coupling agent, in 
absolute dichloromethane; nevertheless the compound was obtained in very low 
yield. Therefore, to favor the formation of 31 and 34 a different coupling agent (1,1‘-
carbonyldiimidazole, DCI) in absolute dioxane was used, improving the yield to 
30%. A significative yield increase (62%) was obtained through the reaction with 
DMAP (4-dimethylaminopyridine) and EDCI [1-ethyl-3-(dimethylaminopropyl)-
carbodiimide] [62]. 
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The compounds bearing the N-methylpiperazine, piperidine and dibutylamine 
side chain were prepared in two steps through the key intermediates 35 and 39, 
which were obtained by reaction of 27a and 1-bromo-3-chloropropane. These last 
derivatives, upon heating under reflux in the respective reagent solvent free, gave the 
substituted polyheterocyclic compounds 36-38, 40 and 41 (Schemes 6, 7). 
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Finally, under the same experimental conditions optimized for the reaction with 
bromobutyrate, compounds 42 and 44 were prepared by reaction of 27b with ethyl 
bromoacetate as side chain (Scheme 8). However, derivative 43 was also isolated. In 
an attempt to limit its formation the condensation was carried out by using NaH as 
base and adding an excess of this reagent (5 fold respect the starting material), but 
compound 43 was isolated in larger yield, since the more drastic basic condition 
allowed a consecutive insertion of the chain and its rearrangement. The hydrolysis of 
the ester groups and the addition of other side chain moieties are being developed. 
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4.2.2. Dihydropyrazoles and amino-cyano-pyridines 
The virtual screening protocol allowed to identify series of derivatives, 
presenting various core structures of type 16-19 (Fig. 26), which satisfy each 
pharmacophore template. By this approach a set of 112 derivatives were obtained, 
and it was observed that among these 16 belonged to dihydropyrazole and 9 to 2-
amino-3-cyanopyridine core structures. Therefore these lead compounds were 
selected for the synthesis. The retrosynthetic analysis of the dihydropyrazole and 
pyridine classes, as reported in figure 28, allowed to evidence a common 
intermediate of type 47 for both classes. 
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a: R1=Cl, R2=R3=R4=H; b: R1=R2=R4=H, R3= NMe2; c: R1=R3=R4=H, R2=F; d: 
R1=OCH3, R2=R3=R4=H; e: R2=R3=OCH3, R1=R4=H; f: R1=R2=R4=H, R3=OCH3; g: 
R3=OH, R1=R2=R4=H; h: R1=OH, R2=OCH3, R3=R4=H; i: R1=R3=R4=H, R2=OCH3; 
j: R1=R2=R4=H, R3=NEt2; k: R1=Br, R2=R3=R4=H; l: R1=H, R2=R3=R4=OCH3 
 
Figure 28. Retrosynthetic analysis 
 
Therefore the first step of the synthetic methodology was the introduction of a 
sulfamidic group in the aminoacetophenone 50 by reaction with methanesulfonyl 
chloride [63] (Scheme 9). 
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Chalcones 47 were synthesized by a base catalyzed Claisen-Schmidt 
condensation reaction of 48 and appropriately substituted aldehydes of type 49 
(Scheme 10). The method is attractive since it specifically generates the (E)-isomer. 
The IR spectra show the characteristic bands due to C=O stretching at 1690-1695 
cm
-1
, C=CH-Ar ones at 1600 and 1475 cm
-1
, while the vinyl group appeared at 1295-
1300 cm
-1
. As evidenced in the 
1
H NMR spectra, all chalcones were geometrically 
pure and with trans-configuration (JHα-Hβ=14.5-15.8 Hz). 
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R3=OH, R1=R2=R4=H; h: R1=OH, R2=OCH3, R3=R4=H; i: R1=R3=R4=H, R2=OCH3; 
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These α,β-unsaturated ketones were the common intermediate for both 
pyrazolines and amino-cyanopyridine synthesis (Scheme 11). 
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The series of pyrazoline analogs were developed with various substituents on B 
ring, while the A ring is characterized by sulfamidic moiety. The acetylated 
dihydropyrazoles 45 were obtained using a known procedure [64], by dissolving the 
chalcone in acetic acid and adding hydrazine hydrate. A pilot reaction to obtain 
dihydropyrazole without substitution at N-1 was carried out adding hydrazine 
hydrate smoothly to the chalcone within 30 min in absolute ethanol at 150°C 
(Scheme 12). The targeted compound was isolated, but in very low yield: in fact, the 
1-unsubstituted derivates have been shown to rapidly undergo reaction with O2, and 
not surprisingly, could not be purified by column chromatography. 
The analysis of the NMR spectra for all the synthesized compounds evidenced 
the presence of  diagnostic double doublets at 3.4-3.01 ppm (J= 4.8-4.6 Hz) and at 
3.96-3.5 ppm (J=17.9-16.0 Hz) attributable to the proton at C-4, and another double 
doublet at 5.7-5.14 ppm (J=12.0 Hz) for the proton at C-5 of the dihydropyrazole.  
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To obtain 2-amino-3-cyanopyridine appropriate chalcones 47 were reacted with 
malononitrile in presence of ammonium acetate in absolute ethanol. The pyridine 
derivatives were generally obtained in good yields. The reaction proceeds through 
Michael addition of the malononitrile anion to the α,β-unsaturated ketones to give the 
adduct 52. Formation of the Schiff base, which rearranges to the enamine 53, can be 
followed by cyclization and subsequent dehydration of the cyclized product, to give 
the 2-amino-3-cyanopyridines 46 (Scheme 13). 
 
SCHEME 13 
 
Ar
O
Ar'
CN CN
Ar
O
Ar'
CN
CN
Ar
NH
Ar'
CN
CN
Ar
NH2
Ar'
CN
CN
N NH2
CN
Ar'
Ar
NH4OCOCH3
53
52
46  
 
 51 
The structure of derivatives 46 was assigned on basis of analytical and spectral 
data. The IR spectra showed a peak at 2215 cm
-1
 due to the cyano stretching 
frequency and bands in the region 3470-3355 cm
-1
 due to the amino groups. The 
1
H 
NMR spectra present a broad singlet for the amino protons at 7.01-6.88 ppm, and in 
the 
13
C NMR a signal due to the CN group was found at 90.2-86.4 ppm. 
The same compounds were also obtained using a different synthetic approach, 
as shown in the Scheme 14, in comparatively similar yields and analogous reaction 
times. This method bypasses the chalcone intermediate exploiting a one-pot coupling 
synthesis of four components. The mixture of aromatic aldehyde, acetophenone, 
malononitrile, and ammonium acetate is dissolved in absolute dioxane and heated 
under reflux overnight. The reaction probably proceeds via imine intermediate, 
formed from aldehyde and ammonium acetate, which reacts with 
alkylidenemalonitrile (from condensation of aromatic aldehyde with malononitrile) 
to give 53. The usual cycloaddition, isomerization, and aromatization afforded the 2-
amino-3-cyanopyridine 46. 
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4.3. Biological Activity 
 
The synthesized compounds were selected by the National Cancer Institute (NCI) in 
the Developmental Therapeutic Program (DTP) to be tested against a panel of 60 
different cell lines derived from human tumors. These have been grouped in nine 
disease subpanels, including leukemia, non small cell lung, colon, central nervous 
system, melanoma, ovarian, renal, prostate, and breast tumor cell lines. 
The antitumoral activity of test compound is given by three parameters for each 
cell line: pGI50 value (GI50 is the molar concentration of the compound that inhibits 
50% net cell growth), pTGI value (TGI is the molar concentration of the compound 
leading to the total inhibition of net cell growth), and the pLC50 value (LC50 is the 
molar concentration of the compound that induces 50% net cell death). Moreover, a 
mean graph midpoint (MG_MID) is calculated for each of the mentioned parameters, 
giving an average activity parameter over all cell lines. For the calculation of the 
MG_MID, insensitive cell lines are included with highest concentration tested. 
Selectivity of a compound respect a certain cell line of the screen is characterized by 
an high deviation of the particular cell line parameter compared to the MD_MID 
value.  
The aim is to prioritize for further evaluation synthetic compounds or natural 
product samples showing selective growth inhibition or cell killing of particular 
tumor cell lines. This screen is unique in that the complexity of a 60 cell line dose 
response produced by a given compound results in a biological response pattern 
which can be utilized in pattern recognition algorithms (such as COMPARE 
program). In addition, following characterization of various cellular molecular targets 
in the 60 cell lines, it may be possible to select compounds most likely to interact 
with a specific molecular target. 
Currently the screening is a two-stage process, beginning with the evaluation of 
all compounds against the 60 cell lines at a single dose of 10 µM. The output from 
the single dose screen is also reported as a mean graph. Compounds are inoculated at 
a single concentration and the cellular coltures are incubated for 48 hours. The data 
are reported as cellular growth percent against the control. The derivatives which 
exhibit significant growth inhibition (less than 32%) are evaluated against the 60 cell 
panel at five concentration levels. 
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In the preliminary screening test both the planar polycycles 27a,b resulted 
inactive, showing a similar response in all panel (Table 7). 
 
Table 7. Cellular growth percentage 
 Leukemia NSCL Colon CNS Melanoma Ovarian Renal Prostate Breast 
27 a 94.7-103.6 76.6-115.8 95.4-113-2 78.9-118.4 95.8-110-1 101.0-118.3 63.5-156.4 83.5-125.2 97.0-114.7 
27b 91-5-107.6 70.8-114.7 97.9-117.3 77.3-114.6 92.7-109.6 83.3-110.5 58.7-160.8 82.1-128.2 98.5-114.7 
 
These results are not surprising, since analogous behaviour was already 
observed in the case of the other annelated triazolo-pyrimidines of type 20d [60]. 
However in previous work in our laboratories it was possible to demonstrate that, 
although the core ring system was pratically inactive, the introduction of suitable 
chain significantly improved the biological properties of the original lead compound. 
This observation resulted particularly evident in the case of compound 54 (Fig. 29), a 
benzothieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine derivative, deaza-analogue of the 
ring system identified by PCA analysis, recognized as potential drug candidate. In 
fact, this derivative was shown to be cytotoxic activity against the majority of human 
tumor cell lines investigated (NCI panel), generally in the nanomolar range (Fig. 30). 
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Figure 30. Mean graph for compound 54 
 
Therefore it has to be expected that also in the case of pyrido-thieno-triazolo-
pyrimidine system the introduction of a side chain in 4 position could modify the 
biological activity profile of these compounds. 
An evaluation of the data, obtained by DTP biological screen, revealed that, 
although compound 38 was active only against the EKVX cell line (-3.24 growth 
percentage), MDA-MB-425 cell line (-84.19 growth percentage) and CAKI-1cell line 
(-87.89 growth percentage), three of the 4-substituted derivatives showed a 
significant antiproliferative activity against the majority of human tumor cell lines 
investigated when tested at five concentration levels (Table 8). 
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Table 8. Cytotoxic activity 
 Tested cell lines pGI50 range MG-MID 
34 59 4.96-7.02 -5.29 
37 59 5.03-6.80 -5.30 
41 58 4.67-6.74 -5.53 
 
In fact, the thienopyridine polycycle bearing the histamine side chain 34 
showed positive response especially against the leukemia (MG_MID=5.93) and 
colon cancer subpanel (MG_MID=5.74), higher than the overall MG_MID value. 
However the most susceptible cell line was OVCAR-8 of the ovarian subpanel, 
against which derivative 34 was active at nsanomolsar concentrations (pGI50=7.02). 
Significant antiproliferative activity was found for the derivatives 37 and 41: in 
fact, although they present the same side chain, the different structural arrangement 
of the four rings strongly influences the biological profile. 
The mean graph of the compound 37 evidenced the remarkable antiproliferative 
effect generally in the micromolar range against all the tested cell lines (Fig. 31). 
Noteworthy is the activity against A498 of the renal subpanel found in the low 
micromolar range (pGI50=6.80), while the cytotoxic effect is shown against all 
melanoma (pGI50 range 5.03-5.93) and leukemia cell lines (pGI50 range 5.21-6.10). 
A different result was obtained in the case of the linear isomer 41, which in the 
average was the most active of the series (Fig 32). In this case the colon and ovarian 
cell lines resulted the most sensitive to the treatment with pGI50 well above the 
average, together with the prostate cancer cell line subpanel (MG_MID=5.81).  
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Figure 31. Mean graph for compound 37 
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Figure 32. Mean graph for compound 41 
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Also the pyrazolines 45 and 2-amino-3-cyanopyridines 46, as well as their 
common intermediate, the chalcone 47, were screening at NCI in the DTP protocol. 
Compounds presenting a chalcone backbone have been reported to exhibit a 
wide range of pharmacological effects, including antioncogenic, anti-inflammatory, 
antiulcerative, analgesic, antiviral, antimalarial and antibacterial activities. The 
presence of a reactive α,β-unsaturated keto function in chalcones was demonstrated 
to be responsible for their known activity. Therefore although the chalcones have not 
been included in our in silico screening, they could be worthy of biological testing. 
And in fact, the chalcone 47f with 4-methoxy substituent was tested at one dose 
against the 60 cell line panel, showing a low growth inhibition in the majority of cell 
lines, while the isosteric compound 47b bearing the dimethylamino group in 4 
position, resulted active with a pGI50 range 4.00-5.65 (Table 9).  
 
Table 9. Cellular growth percentage or cytotoxic activity 
O
HN
SO2 N
O
HN
SO2 O47f 47b
 
 
 Leukemia NSCL Colon CNS Melanoma Ovarian Renal Prostate Breast 
47f 
Mean 
74.33 
-10.1-40.8 60.4-96.4 21.0-111.4 37.5-94.7 75.9-113.5 7.9-109.9 48.6-101.0 42.6 46.9-104.5 
 
 N° Tested cell lines 
N° cell lines giving a 
positive pGI50 
pGI50-range MG-MID 
47b 58 51/58 4.00-5.65 -4.97 
 
In details, as evidenced in the mean graph (Fig. 33), all the cell lines, but one, 
belonging to the leukemia, colon and breast subpanel resulted particularly susceptible 
to derivative 47b, whereas more than half of the melanoma and ovarian lines were 
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significantly inhibited. The higher activity was found against SR leukemia cell line 
(pGI50=5.65). 
 
 
 
Figure 33. Mean graph for compound 47b 
 
The 3,5-diaryl-4,5-dihydropyrazoles have been identified as active core 
structures in antibacterial, hypotensive, antinflammatory and antimitotic agent 
(combretastatins analogues in the tubulin polymerization arrest), as well as Hsp90 
inhibitors [64,65]. However, all the tested dihydropyrazoles, included in this study, 
did not show any significant antiproliferative activity (Table 10). 
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Table 10. Cellular growth percentage 
 Leukemia NSCL Colon CNS Melanoma Ovarian Renal Prostate Breast 
45f 
Mean 
98.13 
57.89-92.93 86.3-130.5 89.7-125.6 84.2-108.9 90.6-138.6 92.1-104.9 69.1-117.9 97.4-108.0 86.2-97.0 
45h 
Mean 
96.59 
49.7-115.7 61.5-115.9 84.4-115.7 90.4-125.8 78.3-106.7 55.4-122.1 79.4-116.1 108.1 84.3-101.5 
45j 
Mean 
86.77 
70.5-119.2 53.8-97.9 75.5-116.2 82.7-104.7 68.4-119.9 35.2-97.1 59.0-116.8 109.9 69.4-97.8 
 
On the contrary well different was the behavior of the amino-cyano-
pyrimidines when tested in the DTP protocol. They, exhibiting a significant growth 
inhibition at a single dose of 10µM, were all selected for testing at five concentration 
levels. These results are not surprising since many natural occurring or synthetic 
compounds, containing the pyridine scaffold, possess interesting pharmacological 
properties. In fact during the last two decades, a large number of substituted 
pyridines have been claimed to possess several biological activity. The antifungal 
and antibacterial properties of these compounds have opened up the possibility of 
their potential use as a novel class of totally synthetic antimicrobial agents active 
against pathogenic bacteria. In addition to this, many naturally occurring B6-
vitamins pyridoxine, pyrodoxal, pyridoxamine, and codecarbaxylase contain a 
pyridine nucleus. Moreover among them, 2-amino-3-cyanopyridines have been 
identified as IKK-β inhibitors [66,67]. 
The results of the screening test on derivatives of type 46 are summarized in 
Table 11. All the compounds showed high antiproliferative activity against the 
majority of the tested cell lines in the low micromolar range. As testified by the 
MG-MID (-7.29), derivative 46b was the most active being effective at nanomolar 
concentration (Fig. 34). 
An evaluation of the data for this class of compounds with respect to MG_MID 
values at TGI and LC50 levels also confirmed that all 2-amino-3-cyanopyridines 
tested present both an high antiproliferative activity and a very low toxicity, since it 
is remarkable the few number of cell lines giving a pLC50 higher than 4.0. 
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Table 11. Cytotoxic activity 
 Tested cell lines pGI50 range MG-MID 
46a 58 4.85-6.76 -6.24 
46b 58 6.18- 8.0 -7.29 
46f 58 6.08-7.90 -6.95 
46h 58 5.94-7.79 -6.81 
 
 
 
Figure 34. Mean graph for compd 46b 
 
In details, as shown in the dose/response graph for compounds 46b (Fig. 35), it 
is notable the optimum activity against all cell lines of the melanoma (MG-MID= 
-7.45), colon (MG-MID= -7.36), CNS (MG-MID= -7.43) and ovarian (MG-MID= 
-7.15) cancer subpanels, where a significant growth inhibition is already evidenced at 
nanomolar concentration (pGI50=7.84 against MDA-MB-435 and pGI50=7.59 against 
OVCAR-3, respectively a melanoma and an ovarian cell line). 
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Figure 35. Dose/response graph compd 46b 
 
Significant results were also obtained in the case of derivative 46f, especially 
against the cell lines belonging to CNS, melanoma and colon subpanels (Fig. 36). 
Against all these cell lines pGI50 was below 7.0. 
 
 
Figure 36. Dose/response graph compd 46f 
 
In conclusion the screening test carried out at NCI revealed that one derivative 
of the tetracyclic system 41 and three 2-amino-3-cyanopyrimidines of type 46 could 
be identified for the development of new anticarcer drugs, and all of them are 
currently being proposed for in vivo testing. 
Although the exact biological target for these active compounds has not 
identified yet, based on our “in silico” analysis we performed further screening tests 
to evidence a probable mechanism of action at biomolecular level. 
Fist it was checked if our identified leads could target HIF. The great majority 
of HIF inhibitors described in literature so far have been identified either in cell 
based screen or by empirical discovery during evaluation of HIF-1 activity in 
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cultured cancer cell lines. One of the first cell based HTS targeting HIF-1 has been 
developed and implemented in the Developmental Therapeutics Program of the 
National Cancer Institute (NCI) at Frederick, where I spent six months during the 
doctoral period. By using U251-HRE human glioma cells genetically engineered to 
stably express a recombinant vector in which the luciferase reporter gene is under 
control of three copies of a canonical HRE, several chemical libraries were screened 
to identify HIF-1 potential inhibitors. A pilot HTS screen was applied to derivatives 
of type 45-47 selected in accord to the results of computational studies as potential 
anticancer drugs. To engineer human cancer cells to express the luciferase reporter 
gene under control of a HIF-1-inducible promoter, pGL2-TK-HRE, containing three 
copies of a canonical HRE, were cotransfected with a vector containing the 
neomycin gene for selection in U251 glioma cells. U251-HRE cells expressed low 
but detectable levels of luciferase in normoxic conditions but expressed significantly 
higher levels in cell cultured under hypoxic conditions. A paralleled screen using 
U251-pGL3 cells, engineered to express luciferase under control of a constitutive 
oxygen-independent promoter, was also conducted to assess specificity. As shown in 
Table 12 and in Fig. 37, the results led to confirm the tested compounds had minimal 
or no activity on the expression of luciferase both in the U251-HRE and U251-pGL3 
control cell line. 
Table 12. EC50 (μM) and activity ratio 
 
HRE PGL3 
Ratio pGL3/HRE 
 Hypoxia 
45a >20 >20 ? 
45e >20 >20 ? 
45f >20 >20 ? 
45g >20 >20 ? 
45h >20 >20 ? 
45i >20 >20 ? 
45j >20 >20 ? 
45k >20 >20 ? 
46c >20 >20 ? 
46e >20 >20 ? 
46i >20 >20 ? 
47a 13 12 0.9 
47b >20 >20 ? 
47c 12 10 0.8 
47d >20 15 <0.76 
47e >20 14 <0.72 
47h >20 18 <0.91 
47i 13 8 0.7 
47k 18 10 0.6 
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Figure 37. Example of dose/response graph 
 
Antiproliferative assays on MCF7 cells, a hormone-sensitive breast tumor cell 
line, present in the NCI panel screening, and able to express high level of Hsp90 
were also undertaken, to verify is heat shock proteins could be the biological target 
of our lead compounds. Cells were treated with dihydropyraze 45j, or with either the 
2-amino-3-cyano-pyrimidines derivatives (46f or 46h), for 24 or 48 hours within the 
1.0x10
-1
-2.5x10
1 
M range. Cell density was evaluated by methylene blue staining 
and compared to the density of cells treated with control vehicle (0.1% DMSO). As 
shown in Fig. 38, derivatives 46h and 46f showed similar growth-inhibitory effect, 
whereas 45j resulted less active. 
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Figure 38. Cell growth curves for compds 46f, 46h and 45j. 
 
Also the antiproliferative effect of dihydropyrazole 45h on Caco-2 cells, a 
human colon cancer cell line able to express high level of Hsp90, was investigated 
obtaing a similar weak inhibitory activity profile (Fig. 39).  
 
 
 
 
 
 
 
 
 
 
Figure 39. Cell growth curve for compd 45h. 
 
These preliminary data indicates that the dihydropyrazole derivatives are very 
weak inhibitors, whereas amino-cyano-pyridine derivatives show a remarkable 
45h
46h 
46f 
45j 
46h concentration ( M) 
45j concentration ( M) 
46f concentration ( M) 
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activity. This profile is consistent with the results obtained by NCI in the DTP 
biological screening. Among the amino-cyanopyridine derivatives, 46h shows the 
higher antiproliferative activity, thus it was selected for further biological screening 
to elucidate its specific influence on the cellular pathways involving Hsp90. 
To measure the effectiveness of 46h in inhibiting MCF-7 cell proliferation, the 
cells were incubated with control vehicle (0,1% DMSO) or 1.0 M 17-AAG or 46h 
at different concentrations (2.0x10
1–1.0x10-2 M) for 24, 48 and 72 hours. Viability 
was assessed by trypan blue exclusion staining and IC50 value was calculated. 
Untreated MCF7 cells (Fig. 40) demonstrated rapid proliferation, with cellular 
numbers at G3 about 3.5 times the initial quantity (G0). As shown in figure, when 
compared to the untreated control, cell numbers decrease in a dose-dependent 
manner after 46h treatment. MCF7 cells quantities were almost the same as the 
original numbers, after the treatment with 1 M 17-AAG or 46h within the 2.0x10
1
-
1.0 M range. 
 
46h
 
46h
 
Figure 40. Dose/response graph for compd 46f 
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As reported in the introduction, a wide range of oncogenic proteins are 
stabilized, matured by, and thus depend on Hsp90. The harsh environmental 
conditions found in tumors tend to destabilize proteins and further augment their 
dependence on HSP90, as supported by the higher Hsp90 levels found in tumor cells 
[68,69]. On the other hand, the molecular signature of Hsp90 inhibition comprises 
induction of Hsp72 coupled with depletion of Hsp90 client proteins. 
The antiproliferative activity shown by 46h on MCF7 cells could be due to the 
breakdown of multiple cell survival pathways, as a consequence of destabilization of 
Hsp90 client proteins. To test this hypothesis, Hsp90 client protein levels were 
evaluated by western blotting analysis. 
 
 
 
 
 
 
 
 
 
Figure 41. Western blot for compd 46h 
 
ErbB-2 overexpression is a common phenomenon in multiple malignancies and 
has been associated with development of resistance to both chemotherapeutic  and 
biologic agents [70]. c-Raf is a kinase protein involved in the MAPK/ERK pathway 
whose deregulation leads to uncontrolled cellular growth [71]. CDK4, a member of 
the cyclin-dependent kinase family, is important for cell cycle G1 phase progression, 
and its up-regulation has been found to be associated with tumorigenesis of a variety 
of cancers [72]. 
All these proteins require the chaperone interaction to exist in an active form 
and are down-regulated in many tumor cells by GA or 17-AAG treatment. As shown 
in Figure 41, MCF7 cells untreated are positive for CDK4, c-Raf and ErbB-2. The 
level of biomarkers decreased after treatment with 46h for 24 hours. The down-
regulation of the Hsp90 proteins levels induced by the 2-amino-3-cyanopyridine 46h 
was observed at low concentration with a dose-dependent effect. Of the three Hsp90 
x
x
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client proteins detected, CDK4 was reduced to a greater extent, whereas ErbB-2 
levels were less affected. It has been reported that CDK4 and c-Raf are very sensitive 
to Hsp90 inhibitors [73,74]. These results are comparable to those achieved 
following exposure of MCF7 cells to 17AAG, under same experimental conditions, 
and are consistent with the known inhibitory activity of Hsp90. 
Antitumor effects can be achieved by cell death and/or cell cycle arrest. 46h 
treatment for 24 h did not yield necrosis in MCF7 cells, as demonstrated by negative 
response to LDH activity assay (data not shown). 
CDK4 and CDK6, and the partner/activator of these CDKs, Cyclin D1, are key 
cell cycle regulator proteins. The interaction of Cyclin D1 and CDK4 is vital during 
the G1 phase, and disruption of either Cyclin D1 or Cdk4 can induce G0/G1 arrest. 
CDK4 and CDK6 are clients of the Hsp90 molecular chaperone. It has been proved 
that Hsp90 inhibitors can affect these CDKs, causing cell cycle arrest [72,74]. We 
observed that 46h treatment induces CDK4 down-regulation at low concentration 
and in a dose-dependent-manner. Indeed, a preliminary analysis of cellular cycle 
distribution, carried out by FCM following PI staining of DNA contents, is consistent 
with this inhibitor effect. Untreated MCF7 cells showed a normal diploid distribution 
presenting fast proliferation characteristics, with cells in S + G2/M accounting for 
about 40% of the total cells. Treatments with 5.0x10
-1 
M 46h for 24 hours caused 
an increase in the number of cells at G0/G1. When the same treatment was performed 
for 48 hours, a new population sub-G0/G1 appeared with a parallel decrease of the 
G0/G1 population (data not shown).  
To explore if our test compounds could be also involved in apoptosis further 
biological experiments were also carried out. In fact, apoptosis is defined by a 
distinct set of morphological changes observed during cell death including loss of 
focal adhesions, formation of cell membrane buds or blebs, and decrease in total cell 
volume. Recent studies suggest that these dramatic morphological changes are an 
early prerequisite to apoptosis and precede key biochemical time-points [74]. In 
particular when cells are stressed, a common response is to undergo cell death by one 
of two pathways, either ―necrosis‖ or ―apoptosis‖. Recently, both routes to cell death 
have been revealed to share similar mechanisms, with heat-shock proteins and their 
cofactors responsible for inhibiting both apoptotic and necrotic pathways [75]. MCF7 
cells treated with 46h within the 0.5x10
-1–5.0x10-3 M range when compared to 
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untreated cells show dramatical morfological feature changes associated with 
apoptosis (Fig. 42).  
 
 
 
Figure 41. Microscopy images of MCF7 cells treated with different concentration of 
compound 46h for24h. 
 
Collectively, these results suggest that the antiproliferative effect of 46h 
derivative treatment on MCF cells is due to G0/G1 cell cycle arrest and subsequent 
apoptosis. 
Currently further biological screenings are undertaken for other amino-cyano-
pyrimidine analogues and for the new 4-substituted polyheterocycles to elucidate 
their specific influence on the cellular pathways involving Hsp90. 
CTR 
46h 50 nM 46h 10 nM 
46h 500 nM 46h 100 nM 
MCF7 cells, G2,  
24 hrs treatment 
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5. CONCLUSIONS 
 
In conclusion, new potential Hsp90 inhibitors are identified by utilizing the ligand-
based virtual screening. These findings empathize the usefulness of virtual screening 
in the development of targeted inhibitors with novel structures.  
The investigation of binding modes in the ATP-binding pocket of Hsp90 has 
provided valuable information to design various effective derivatives, presenting 
these features (Pharmacophore approaches). By multivariate analysis the planar ring 
systems, bearing suitable side chains and extracted from an “in house” database, 
were identified as potential protein-binders.  
The selected compounds were synthesized, generally in good – excellent 
yields, by using known chemical approaches.  
The antiproliferative activity, against a panel of nearly 60 cell lines, was 
evaluated by NCI in the DTP protocol. The most active derivative was also tested to 
explore its involvement in signal-transduction pathways correlated with Hsp90. 
The biological results demonstrated that some of the new derivatives, 
discovered and synthesized during this work, can be effective as antiproliferative 
agents, mainly against melanoma tumor cell lines, at concentrations ranging from 
micro to nanomolar. Moreover they seem to be involved in pathways correlated with 
Hsp90 activity. Three of these compounds are currently screened in vivo in the 
preclinical assays, whereas further insights in the mechanism of action are worthy of 
investigation. 
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6. EXPERIMENTAL SECTION 
 
6.1. Chemistry 
All melting points were taken on a Buchi-Tottoli capillary apparatus and are 
uncorrected; IR spectra were determined in bromoform with a Jasco FT/IR 5300 
spectrophotometer; 
1
H and 
13
C NMR spectra were measured in DMSO-d6 solution, 
unless otherwise specified, (TMS as internal reference) at 200 and 50.3 MHz, 
respectively, using a Bruker AC-E series 200 MHz spectrometer. 
13
C NMR spectra 
are reported, indicating the multiplicity, (s, singlet; d, doublet; t, triplet; q, quartet) 
assigned by DEPT135 experiments. Column chromatography was performed with 
Merck silica gel 230–400 mesh ASTM or with a Biotage FLASH40i chromatography 
module (prepacked cartridge system), unless otherwise specified. Microanalyses 
were in agreement with theoretical values ±0.4%. 
 
Ethyl 3-aminothieno[2,3-b]pyridine-2-carboxylate (23)  
According to the literature procedure [61], ethyl thioglycolate 22 (1.2 mL, 11 mmol) 
was added to a stirred mixture of NaH (0.36 g, 15 mmol) and DMSO (10 mL). After 
evolution of H2 had ceased, a solution of 2-chloro-3-cyanopyridine 21 (1.40 g, 10 
mmol) in DMSO (20 mL) was added dropwise. After 3h the mixture was poured 
onto stirred water/ice. The light yellow precipitate was collected and dried to give 23 
(2.25 g, 100%), Mp. 183°C. IR: 3395 (NH2), 1689 (CO) cm
-1 1
H NMR ppm: 8.68 
(dd, J = 4.6, 1.6 Hz, 1H, H-6), 8.54 ( dd, J = 8.2, 1.6 Hz, 1H, H-4), 7.46 (dd, J = 8.2 
Hz, 4.6 Hz, 1H, H-5), 7.31 (br s, 2H, NH2), 4.30 (q, J = 7.1 Hz, 2H, CH2), 1.29 (t, J = 
7.1 Hz, 3H, CH3). 
13
C NMR ppm: 164.3(s), 159.6(s), 150.7(d), 147.7(s), 131.4(d), 
125.5(s), 119.3(d), 93.3(s), 59.9(t), 14.4(q). 
 
Ethyl 3-Azidothieno[2,3-b]pyridine-2-carboxylate (24) 
A solution of ethyl 3-aminopyrido[3,2-b]thiophene-2-carboxylate 23 (0.3 g, 1.35 
mmol) in 6N hydrochloric acid (12 mL) was cooled in an ice bath to -5-0°C. A 
solution of sodium nitrite (0.186 g, 2.7 mmol) in water (2 mL) was added slowly 
under vigorous stirring. After 30 min sodium azide (0.35 g, 5.4 mmol) in water (2 
mL) was added dropwise over 10 min. The reaction mixture was stirred for further 
3h at room temperature and then slowly poured onto water/ice. The precipitate was 
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separated, washed on the filter with cold water until the wash water was neutral, and 
dried in the absence of light to give 24 (0.22 g, 60%), Mp 93°C. IR: 2127 (N3), 1705 
(CO) cm
-1
. 
1
H NMR ppm: 8.68 (dd, J = 4.6, 1.6 Hz, 1H, H-6), 8.54 (dd, J = 8.2, 1.6 
Hz, 1H, H-4), 7.46 (dd, J = 8.2, 4.5 Hz, 1H, H-5), 4.30 (q, J = 7.1 Hz, 2H, OCH2 ), 
1.30 (t, J =7.1 Hz, 3H, CH3). 
13
C NMR ppm: 164.3(s), 159.6(s), 150.7(d), 147.7(s), 
131.4(d), 125.5(s), 119.3(d), 93.3(s), 59.9(t), 14.41(q). 
Anal. Calcd. for C10H8N4O2S: C, 48.38; H, 3.25; N, 22.57; S, 12.92, found: C, 48.40; 
H, 3.28; N, 22.55; S, 12.94. 
 
5-Oxopyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine-3-
carbonitrile (27a) 
To a solution of 1.3 M sodium ethoxide in ethanol (2.7 mL) malononitrile (0.115 g, 
1.73 mmol) in absolute ethanol (2 mL) were added at room temperature. After being 
stirred for 15 min the solution was added to a solution of azido derivative 24 (0.215 
g, 0.87 mmol) in absolute ethanol (3 mL) and the mixture was stirred overnight at 
room temperature. Evaporation of the solvent under reduced pressure gave a solid 
which was purified by column chromatography using dichloromethane/methanol 9:1 
as eluant to afford compound 27a as a white solid (0.140 g, 0.52 mmol). Yield 60%, 
mp >410°C. IR: 3404 (NH), 2231 (CN), 1685 (CO). 
1
H NMR ppm: 8.79 (dd, J= 3.2 
Hz, 1H, H-8), 8.65 (dd, J= 6.5 Hz, 1H, H-10), 7.6 (dd, J= 3.2, 6.5 Hz, 1H, H-9). 
13
C 
NMR ppm: 162.2(s), 152.7(s), 151.9(s), 150.9(d), 149.5(s), 131.9(d), 128.2(d), 
120.3(s), 114.7(s), 105.1(s), 104.4(s). 
Anal. Calcd. for C11H4N6OS: C, 49.25; H, 1.50; N, 31.33; S, 11.95¸ found: C, 49.30; 
H, 1.54; N, 31.32; S, 11.98. 
 
By identical synthetic procedure and reducing the solvent volume (2 mL), the 
intermediate ethyl 3-(5-amino-4-cyano-1H-1,2,3-triazol-1-yl)thieno[2,3-
b]pyridine-2-carboxylate (26a) was filtered off, air dried and recrystallized from 
ethanol. Yield 35%, mp >410°C. IR: 3550 and 3420 (NH2), 2254 (CN), 1648 (CO). 
1
H NMR ppm: 8.89 (s, 1H, NH), 8.77 (dd, J = 4.6, 1.6 Hz, 1H, H-6), 8.63 (dd, J = 
7.9, 1.6 Hz, 1H, H-4), 7.60 (dd, J = 7.9, 4.6 Hz, 1H, H-5), 4.35 (q, J = 7.0 Hz, 2H, 
CH2), 1.39 (t, J = 7.0 Hz, 3H, CH3). 
13
C NMR ppm: 162.3(s), 161.3(s), 152.2(s), 
152.1(s), 150.6(d), 146.7(s), 131.5(d), 128.5(s), 122.4(s), 120.2(d), 103.8(s), 59.5(t), 
14.4(t). 
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Anal. Calcd. for C13H10N6O2S: C, 49.67; H, 3.21; N, 26.74; S, 10.20; found: C, 
49.65; H, 3.23; N, 26.71; S, 10.22. 
 
3-Phenylpyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5(4H)-one 
(27b) 
To a solution of 1.3 M sodium ethoxide in ethanol (4.6 mL) phenylacetonitrile 
(0.35g, 3.0 mmol) in absolute ethanol (2 mL) was added at room temperature. After 
being stirred for 15 min, the solution was added to a solution of azido derivative 24 
(0.37g, 1.5 mmol) in absolute ethanol (3 mL) and the mixture was stirred overnight 
at room temperature. Evaporation of the solvent under reduced pressure gave a solid 
which was purified by column chromatography using dichloromethane/methanol 9:1 
as eluant to afford compound 27b as a yellow solid (0.3 g, 0.94 mmol). Yield 63%, 
mp >410°C. IR: 3368 (NH), 1630 (CO) cm
-1
. 
1
H NMR ppm: 8.74 (d, J = 3.1 Hz, 1H, 
H-8), 8.66 (d, J = 7.8 Hz, 1H, H-10), 8.54-7.96 (m, 2H, H-2‘, H-6‘), 7.60-7.44 (m, 
3H, H-3‘, H-4‘, H-5‘), 7.25 (d, J = 7.3 Hz, 1H, H-9). 13C NMR ppm: 162.3(s), 
151.8(s), 150.3(d), 146.2(s), 144.2(s), 133.2(s), 132.3(s), 131.3(d), 129.1(s), 
128.3(d), 125.3(d), 124.0(d), 120.00(d). 
Anal. Calcd. for C16H9N5OS: C, 60.18; H, 2.84; N, 21.93; S, 10.04; found: C, 60.16; 
H, 2.87; N, 21.94; S, 10.06. 
 
Reaction of 27b with ethyl 4-bromobutyrate 
To a stirred suspension of 27b (0.3 g, 0.93 mmol) in absolute DMF (10 mL), 
potassium carbonate (0.39 g, 2.81 mmol) and ethyl 4-bromobutyrate (0.9 g, 4.65 
mmol) were added. The mixture was heated at 60°C for 16h, cooled to room 
temperature, and then slowly poured onto water/ice. The precipitate was purified by 
column chromatography using dichloromethane/ethyl acetate 98:2 as eluant to afford 
compound ethyl (3-phenyl-10-oxopyrido[2’,3’:4,5]thieno[3,2-d][1,2,3]triazolo 
[1,5-a]pyrimidin-4-yl)butanoate (32). Yield 11%, mp 137.2-138.0°C. 
1
H NMR 
ppm: 9.36 (dd, J = 8.0, 1.4 Hz, 1H, H-7), 8.61 (dd, J = 4.6, 1.4 Hz, 1H, H-5), 8.41 (d, 
J = 7.3 Hz, 2H, H-2‘, H-6‘), 7.68 (dd, J = 8.0, 4.6 Hz, 1H, H-6), 7.50 (t, J = 7.3 Hz, 
2H, H-3‘, H-5‘), 7.34 (d, J = 7.3 Hz, 1H, H-4‘), 4.79 (t, J = 6.0 Hz, 2H, NCH2), 4.18 
(q, J = 7.1 Hz, 2H, OCH2), 2.62 (t, J = 7.2 Hz, 2H, CH2), 2.27-2.40 (m, 2H, 
CH2CH2CH2), 1.27 (t, J = 7.1 Hz, 3H, CH3). 
13
C NMR ppm: 172.7(s), 162.5(s), 
158.9(s), 151.5(d), 134.6(d), 133.6(s), 130.7(s), 129.7(s), 128.7(d), 127.7(d), 
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125.7(d), 122.5(s), 121.3(d), 112.85(s), 110.0(s), 67.5(t), 60.6(t), 30.8(t), 23.9(t), 
14.2(q).  
Anal. Calcd. for C22H19N5O3S: C, 60.96; H, 4.42; N, 16.16; S, 7.40; found: C, 60.96; 
H, 4.44; N, 16.17; S, 7.43. 
 
Further elution with dichloromethane/ethyl acetate 95:5 gave ethyl (3-phenyl-5-
oxopyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-4-yl)butanoate 
(29). Yield 63%, mp 109.6-110.8°C. 
1
H NMR (CDCl3) ppm: 8.78 (dd, J = 4.6, 1.5 
Hz, 1H, H-8), 8.61 (dd, J = 7.9, 1.5 Hz, 1H, H-10), 7.42 (dd, J = 7.98, 1.64 Hz, 1H, 
H-9), 7.63-7.50 (m, 5H, Ph), 4.94 (t, J = 6.6 Hz, 2H, NCH2), 3.92 (q, J = 7.1 Hz, 2H, 
OCH2), 2.41 (t, J = 7.2 Hz, 2H, CH2), 2.06 (m, 2H, CH2CH2CH2), 1.08 (t, J = 7.1 Hz, 
3H, CH3). 
13
C NMR ppm: 172.0(s), 161.7(s), 151.9(s), 151.5(d), 150.8(d), 145.3(s), 
136.6(s), 131.9(d), 129.6(s), 128.7(d), 128.0(s), 127.5(s), 126.1(d), 120.8(d), 
112.6(s), 59.9(t), 55.1(t), 30.3(t), 23.5(t), 13.8(q).  
Anal. Calcd. for C22H19N5O3S: C, 60.96; H, 4.42; N, 16.16; S, 7.40; found: C, 60.94; 
H, 4.41; N, 16.13; S, 7.44. 
 
General procedure for the hydrolysis of the ethyl butanoates. 
To a suspension of 29 or 32 (0.5 mmol) in absolute ethanol (5 mL), a solution of 
potassium hydroxide (0.08 g, 1.5 mmol) in water (1 mL) was added dropwise. The 
mixture was stirred at room temperature for 8h. The ethanol was evaporated under 
reduced pressure, the residue was dissolved in water (10 mL) and then carefully 
adjusted to pH=1 with 6N hydrochloric acid. The precipitate was filtered off, air 
dried and recrystallized from dicloromethane to afford the corresponding acid. 
4-(3-Phenyl-5-oxopyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-4-
yl)butanoic acid (30) was isolated in 86% yield, mp 171.0-171.6°C. 
1
H NMR ppm: 
9.33 (br s, 1H, OH), 8.64 (dd, J = 4.5, 1.5 Hz, 1H, H-8), 7.88 (dd, J = 8.2, 1.4 Hz, 
2H, H-2‘, H-6‘), 7.51 (dd, J = 8.4, 1.5 Hz, 1H, H-10), 7.46-7.32 (m, 3H, H-3‘, H-4‘, 
H-5‘), 7.27 (dd, J = 8.4, 4.5 Hz, 1H, H-9), 4.4 (t, J = 6.6 Hz, 2H, NCH2), 2.3 (t, J = 
6.6 Hz, 2H, CH2COOH), 2.13-1.99 (m, 2H, CH2CH2CH2). 
13
C NMR ppm: 173.6 (s), 
166.1 (s), 159.0 (s), 149.9 (d), 143.0 (s), 137.6 (s), 132.5 (d), 129.6 (s), 128.8 (d), 
128.2 (d), 126.1 (d), 125.5 (s), 119.2 (d), 99.4 (s), 53.92 (t), 30.28 (t), 24.59 (t).  
Anal. Calcd. for C20H15N5O3S: C, 59.25; H, 3.73; N, 17.27; S, 7.91; found: C, 59.24; 
H, 3.71; N, 17.30; S, 7.92. 
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4-(3-Phenyl-10-oxopyrido[3’,2’:4,5]thieno[3’,2’:4,5]thieno[2,3-e][1,5-a]pyrimi-
din-4-yl)butanoic acid (33) was isolated in 70% yield, mp 180.9-181.6°C. 
1
H NMR 
ppm: 8.73 (dd, J = 8.2, 1.7 Hz, 1H, H-7), 8.63 (dd, J = 7.8 Hz, 2H, H-2‘, H-6‘), 7.5-
7.24 (m, 5H, H-5, H-6, H-3‘, H-4‘, H-5‘), 4.75 (t, J = 6.4 Hz, 2H, NCH2), 2.02 (t, J = 
6.4 Hz, 2H, CH2COOH), 1.60-1.49 (m, H, CH2CH2CH2). 
13
C NMR ppm: 174.2(s), 
165.8(s), 159.9(s), 150.2(d), 144.1(s), 136.8(s), 131.2(d), 129.8(s), 128.8(d), 
125.3(d), 124.0(d), 126.5(s), 119.9(d), 99.4(s), 62.7(t), 38.0(t); 28.8(t).  
Anal. Calcd. for C20H15N5O3S: C, 59.25; H, 3.73; N, 17.27; S, 7.91; found: C, 59.22; 
H, 3.70; N, 17.28; S, 7.94. 
 
General procedure for reaction of acids with histamine 
To a stirred suspension of 30 or 33 (0.44 mmol) in absolute dioxane (5 mL), DMAP 
(0.05 g, 0.45 mmol) and EDCI (0.17 g, 9.2 mmol) were added under nitrogen 
atmosphere. After 2h histamine (0.102 g, 9.2 mmol) was added carefully. The 
reaction mixture was stirred for 5 days at room temperature. The solvent was 
evaporated under reduced pressure and the residue was purified by column 
cromatography using dichloromethane/methanol 9:1 as eluant. 
 
N-[2-(1H-Imidazol-4-yl)ethyl]-4-(3-Phenyl-5-oxopyrido[2’,3’:4,5]thieno[3,2-
d][1,2,3]triazolo[1,5-a]pyrimidin-4-yl) butanamide (31) had mp 234.7-240.3°C 
1
H 
NMR ppm:8.90 (dd, J = 4.6, 1.7 Hz, 1H, H-8), 8.85 (dd, J = 8.0, 1.7 Hz, 1H, H-10), 
8.57 (dd, J = 8.3, 1.6 Hz, 2H, H-2‘, H-6‘), 7.72 (dd, J = 8.0, 4.6 Hz, 1H, H-9), 7.68-
7.55 (m, 4H, H-3‘, H-4‘, H-5‘, CH), 6.7 (s, 1H, CH), 5.0 (t, J = 6.7 Hz, 2H, NCH2), 
3.44 (t, J = 6.5 Hz, 2H, CH2CO), 3.13 (t, J = 7.0 Hz, 2H, CH2CH2), 2.17 -2.03 (m, 
4H, CH2CH2CH2, CH2CH2 ). 
13
C NMR ppm: 173.6 (s), 166.1 (s), 161.7(s), 159.0 (s), 
149.9 (d), 143.0 (s), 137.6 (s), 132.5 (d), 129.6 (s), 128.8 (d), 128.2 (d), 127.8(d), 
126.1 (d), 125.5 (s), 119.2 (d), 115.8(s), 99.4 (s), 71.7(t), 53.9 (t), 38.8(t), 30.2 (t), 
24.5 (t).  
Anal. Calcd. for C25H22N8O2S: C, 60.23; H, 4.45; N, 22.48; S, 6.43; found: C, 60.27; 
H, 4.48; N, 22.50; S, 6.44. 
 
N-[2-(1H-Imidazol-4-yl)ethyl]-4-(3-Phenyl-10-oxopyrido[2’,3’:4,5]thieno[3,2d]-
[1,2,3]triazolo[1,5a]pyrimidin-4-yl) butanamide (34) had mp 234.7-240.3°C 
1
H 
NMR ppm:8.77 (dd, J = 4.6, 1.8 Hz, 1H, H-7), 8.82 (dd, J = 7.9, 1.8 Hz, 1H, H-5), 
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8.64 (dd, J = 8.0, 1.6 Hz, 2H, H-2‘, H-6‘), 7.72 (dd, J = 7.9, 4.6 Hz, 1H, H-6), 7.65-
7.52 (m, 4H, H-3‘, H-4‘, H-5‘, CH), 6.45 (s, 1H, CH), 5.22 (t, J = 6.7 Hz, 2H, 
NCH2), 3.47 (t, J = 6.5 Hz, 2H, CH2CO), 3.22 (t, J = 7.2 Hz, 2H, CH2CH2), 2.25-2.01 
(m, 4H, CH2CH2CH2, CH2CH2 ). 
13
C NMR ppm: 170.5 (s), 166.3 (s), 161.5 (s), 
155.9 (d), 144.8 (s), 136.6 (s), 132.9 (d), 131.8 (s), 129.5(d), 127.7 (d), 127.2 (d), 
126.5 (d), 125.9 (s), 117.5 (d), 99.8 (s), 70.5(t), 53.8 (t), 31.9(t), 30.4 (t), 25.7 (t).  
Anal. Calcd. for C25H22N8O2S: C, 60.23; H, 4.45; N, 22.48; S, 6.43; found: C, 60.30; 
H, 4.45; N, 22.58; S, 6.42. 
 
Reaction of 27b with 1-bromo-3-chloropropane 
To a stirred suspension of 27b (0.62 g, 1.93 mmol) in absolute DMF (12 mL), 
potassium carbonate (0.8 g, 5.81 mmol) and 1-bromo-3-chloropropane (1.52 g, 9.68 
mmol) were added. The mixture was heated at 60°C for 16h, cooled to room 
temperature, and then slowly poured onto water/ice. The precipitate was purified by 
column chromatography using dichloromethane/ethyl acetate 98:2 as eluent to afford 
4-(3-chloropropyl)-3-phenylpyrido[2’,3’:4,5]thieno[3,2-d][1,2,3]triazolo[1,5-
a]pyrimidin-10(4H)-one (39). Yield 20%, mp 195.4-196.6°C 
1
H NMR (CDCl3) 
ppm: 9.4 (dd, J = 8.2, 1.7 Hz, 1H, H-7), 8.92 (dd, J = 4.6, 1.7 Hz, 1H, H-5), 8.45 (dd, 
J = 8.2, 4.6 Hz, 1H, H-6), 7.54 (dd, J = 7.2, 1.6 Hz, 2H, H-2‘, H-6‘), 7.4 (dd, J = 2.5, 
1.6 Hz, 2H, H-3‘, H-5‘), 7.35 (dd, J = 5.9, 1.6 Hz, 1H, H-4‘), 4.92 (t, J = 6.2 Hz, 2H, 
NCH2), 3.84 (t, J = 6.2 Hz, 2H, CH2Cl), 2.56-2.48 (m, 2H, CH2CH2CH2). 
13
C NMR 
ppm: 161.7(s), 157.3(s), 151.5(d), 137.6(s), 134.4(d), 133.9(s), 133.1(s), 130.7(s), 
128.7(d), 127.7(d), 125.8(d), 122.4(s), 121.3(d), 99.9(s), 65.1(t), 41.1(t), 29.7(t).  
Anal.Calcd. for C19H14ClN5OS: C, 57.65; H, 3.56; Cl, 8.96; N, 17.69; S, 8.10; found: 
C, 57.67; H, 3.60; Cl, 8.99; N, 17.67; S, 8.11. 
 
Further elution with dichloromethane/ethyl acetate 98:2 gave 4-(3-chloropropyl)-3-
phenylpyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5(4H)-one 
(35). Yield 65%, mp 200.8-201.7°C 
1
H NMR (CDCl3) ppm: 8.75 (dd, J = 8.2, 1.7 
Hz, 1H, H-8), 8.63 (dd, J = 4.6, 1.7 Hz, 1H, H-10), 8.54 (dd, J = 8.2, 4.6 Hz, 1H, H-
3), 7.55-7.47 (m, 4H, H-93, H-3‘, H-4‘, H-5‘), 5.13 (t, J = 6.3 Hz, 2H, NCH2), 3.63 
(t, J = 6.3 Hz, 2H, CH2Cl), 2.4-2.28 (m, 2H, CH2CH2CH2). 
13
C NMR ppm: 163.3(s), 
152.9(s), 151.7(s), 151.5(d), 145.7(s), 139.2(s), 132.1(d), 130.1(d), 129.7(d), 
128.8(s), 127.0(d), 120.2(d), 115.0(s), 99.9(s), 53.6(t), 41.2(t), 31.2(t). 
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Anal.Calcd. for C19H14ClN5OS: C, 57.65; H, 3.56; Cl, 8.96; N, 17.69; S, 8.10; found: 
C, 57.64; H, 3.58; Cl, 8.98; N, 17.70; S, 8.13. 
 
Reaction of chloropropyl derivative wtih 1-methylpiperazine 
A stirred suspension of 35 or 39 (0.1 g, 0.25 mmol) in 1-methylpiperazine (3 mL) 
was heated at reflux for 2h. After cooling the mixture was poured onto water/ice and 
the precipitate was filtered off and purified by alumina column chromatography. 
In the case of 35 elution with dichloromethane/ethyl acetate 98:2 afforded 4-[3-(N-
methylpiperazino)propyl]-3-phenylpyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]tri-
azolo[1,5-a]pyrimidin-5(4H)-one (37). Yield 85%, mp 88.3-90.2°C. 
1
H NMR 
(CDCl3) ppm: 8.78 (dd, J = 4.5, 1.4 Hz, 1H, H-8), 8.72 (dd, J = 7.9, 1.4 Hz, 1H, H-
10), 8.56 (d, J = 6.6 Hz, 2H, H-2‘, H-6‘), 7.6-7.47 (m, 4H, H-9, H-3‘, H-4‘, H-5‘), 
5.12 (t, J = 6.8 Hz, 2H, NCH2), 2.4 (t, J = 6.5 Hz, 2H, CH2), 2.28 (s, 8H, 2x 
NCH2CH2N), 2.14 (s, 3H, CH3), 2.03-1.90 (m, 2H, CH2CH2CH2). 
13
C NMR ppm: 
163.4(s), 152.8(s), 151.6(s), 151.4(d), 145.2(s), 138.2(s), 132.1(d), 129.8(d), 
128.8(d), 128.5(s), 128.3(s), 126.8(d), 120.1(d), 99.7(s), 53.2(t); 55.0(t), 54.7(t), 
52.9(t), 45.9(q), 26.1(t). 
Anal. Calcd for C24H25N7OS: C, 62.72; H, 5.48; N, 21.33; S, 6.98; found: C, 62.81; 
H, 5.52; N, 21.35; S, 6.97. 
 
In the case of 39 elution with dichloromethane gave 5-[3-(N-
methylpiperazino)propyl]-3-phenylpyrido[2’,3’:4,5]thieno[3,2d][1,2,3]triazolo-
[1,5a]pyrimidin-10(4H)-one (41), as a yellow solid. Yield 26%, mp 149.6-150.8°C. 
1
H NMR ppm:
 1
H NMR (CDCl3) ppm: 9.31 (dd, J = 8.1, 1.7 Hz, 1H, H-7), 8.87 (dd, 
J = 4.6, 1.7 Hz, 1H, H-5), 8.39 (d, J = 7.4 Hz, 2H, H-2‘, H-6‘), 7.64 (dd, J = 8.1, 4.6 
Hz, 1H, H-6), 7.47 (t, J = 7.2 Hz, 2H, H-3‘, H-5‘), 7.33 (d, J = 7.4 Hz, 1H, H-4‘), 
4.76 (t, J = 6.3 Hz, 2H, NCH2), 2.63 (t, J = 6.6 Hz, 2H, CH2), 2.28 (bs, 8H, 2x 
NCH2CH2N), 2.29 (s, 3H, CH3), 2.24-1.03 (m, 2H, CH2CH2CH2). 
13
C NMR ppm: 
161.6(s), 157.5(s), 151.3(s), 137.7(s), 134.3(d), 133.6(s), 132.8(d), 130.8(s), 
128.6(d), 127.5(d), 125.6(d), 122.4(s), 121.2(d), 112.9(s), 66.9(t); 55.1(t), 55.0(t), 
55.2(t), 46.0(q), 26.0(t). 
Anal. Calcd for C24H25N7OS: C, 62.72; H, 5.48; N, 21.33; S, 6.98; found: C, 62.75; 
H, 5.51; N, 21.37; S, 6.99. 
 
 78 
Reaction of chloropropane derivative with dibutylamine 
A stirred suspension of 35 (0.1 g, 0.25 mmol) in dibutylamine (3 mL) was heated at 
reflux for 2h. After cooling the mixture was poured onto water/ice and the precipitate 
was filtered off and purified by alumina column chromatography. Elution with 
dichloromethane/ethyl acetate 98:2 afforded 5-[3-(dibutylamino)propyl]-3-
phenylpyrido[3’,2’:4,5]thieno[2,3-e]-[1,2,3]triazolo[1,5-a]pyrimidin-5(4H)-one 
(38), mp 109.5-110.5°C. 1H NMR ppm: 8.81 (dd, J = 4.6, 1.7 Hz, 1H, H-8), 8.73 
(dd, J = 7.9, 1.7 Hz, 1H, H-10), 8.58 (dd, J = 8.2, 1.7 Hz, 2H, H-2‘, H-6‘), 7.61-7.49 
(m, 4H, H-9, H-3‘, H-4‘, H-5‘), 2.49 (t, J = 6.7 Hz, 2H, NCH2), 2.34 (t, J = 6.7 Hz, 
4H, N(CH2CH2CH2CH3)2), 1.95-1.81 (m, 2H, NCH2CH2CH2), 1.34-1.24 (m, 10H, 
N(CH2CH2CH2CH3)2, NCH2CH2CH2), 0.86 (t, J=6.7 Hz, 6H, 
N(CH2CH2CH2CH3)2).
13
C NMR ppm: 163.4(s), 152.9(s), 151.7(s), 151.4(d), 
145.8(s), 145.2 (s), 138.4(s), 132.1(d), 129.8(d), 128.8(d), 128.5(s), 128.3(s), 
126.9(d), 120.1(d), 55.1(t), 53.7(t), 50.8 (t), 29.1(t), 26.3(t); 20.6(t); 13.0(q). 
Anal. Calcd. for C27H32N6OS: C, 66.36; H, 6.60; N, 17.20; S, 6.56; found: C, 66.38; 
H, 6.65; N, 17.18; S, 6.59. 
 
Reaction of chloropropyl derivative with piperidine 
A stirred suspension of 35 or 39 (0.1 g, 0.25 mmol) in piperidine (3 mL) was heated 
at reflux for 2h. After cooling the mixture was poured onto water/ice and the 
precipitate was filtered off and purified by alumina column chromatography. 
In the case of 35 elution with dichloromethane/methanol 98:2 afforded 5-[3-
piperidine-propyl]-3-phenylpyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-
a]pyrimidin-5(4H)-one (36), mp 82.7-84.0°C. 
1
H NMR (CDCl3) ppm: 8.79 (dd, J = 
4.6, 1.7 Hz, 1H, H-8), 8.7 (dd, J = 8.0, 1.7Hz, 1H, H-10), 8.55 (dd, J = 8.3, 1.7 Hz, 
2H, H-2‘-H-6‘), 7.60-7.46 (m, 4H, H-9, H-3‘, H-4‘, H-5‘), 5.09 (t, J = 6.9 Hz, 2H, 
NCH2), 2.35 (t, J = 6.9 Hz, 2H, CH2), 2.23 (s, 4H, 2xCH2), 2.02-1.88 (m, 2H, 
CH2CH2CH2), 1.36 (s, 2H, CH2), 1.33 (s, 2H, CH2). 
13
C NMR ppm: 163.4(s), 
152.8(s), 151.7(d), 151.3(s), 145.8(s), 138.2(s), 132.1(d), 129.8 (d), 128.8 (d), 
128.6(s), 128.3 (s), 126.8 (d), 120.1 (d), 114.5 (s), 55.9(t), 55.3(t), 54.5(t), 26.1(t), 
25.7 (t), 24.2(t). 
Anal. Calcd. for C24H24N6OS: C, 64.84; H, 5.44; N, 18.90; S, 7.21; found: C, 64.82; 
H, 5.45; N, 18.89; S, 7.24. 
 
 79 
 
In the case of 39 elution with dichloromethane/methanol 9:1 gave 5-[3-piperidine-
propyl]-3-phenylpyrido[2’,3’:4,5]thieno[3,2d][1,2,3]triazolo-[1,5a]pyrimidin-
10(4H)-one (40), mp 85.7-86.5°C. 
1
H NMR (CDCl3) ppm: 8.81 (dd, J = 4.6, 1.7 Hz, 
1H, H-7), 8.72 (dd, J = 8.0, 1.7Hz, 1H, H-5), 8.61 (dd, J = 8.3, 1.7 Hz, 2H, H-2‘, 
H-6‘), 7.58-7.46 (m, 4H, H-6, H-3‘, H-4‘, H-5‘), 5.19 (t, J = 6.9 Hz, 2H, NCH2), 2.48 
(t, J = 6.9 Hz, 2H, CH2Cl), 2.25 (s, 4H, CH2 ), 2.15-1.87 (m, 2H, CH2CH2CH2), 1.38 
(s, 2H, CH2), 1.35 (s, 2H, CH2). 
13
C NMR ppm: 164.8(s), 152.5(s), 150.9(d), 
151.2(s), 147.7(s), 136.5(s), 131.1(d), 128.9 (d), 128.1 (d), 127.8(s), 127.5 (s), 126.1 
(d), 118.9 (d), 112.6 (s), 55.4(t), 55.1(t), 54.6(t), 26.1(t), 25.9 (t), 24.5(t). 
Anal. Calcd. for C24H24N6OS: C, 64.84; H, 5.44; N, 18.90; S, 7.21; found: C, 64.83; 
H, 5.41; N, 18.84; S, 7.28. 
 
Reaction of 27b with ethyl bromoacetate 
To a stirred suspension of 27b (0.225 g, 0.7 mmol) in absolute DMF (5 mL), 
potassium carbonate (0.29 g, 2.1 mmol) and ethyl bromoacetate (0.58 g, 3.5 mmol) 
were added. The mixture was heated at 60°C for 16h, cooled to room temperature, 
and then slowly poured onto water/ice. The precipitate was purified by column 
chromatography using dichloromethane/ethyl acetate 98:2 as eluant to afford ethyl 
(3-phenyl-10-oxopyrido[2’,3’:4,5]thieno[3,2-d][1,2,3]triazolo[1,5-a]pyrimidin-4-
yl)acetate (44). Yield 11%, mp 194.4-195.7°C. 
1
H NMR ppm: 9.39 (dd, J = 8.2 Hz, 
1.7 Hz, 1H, H-7), 8.93 (dd, J = 4.6, 1.7 Hz, 1H, H-5), 8.37 (dd, J = 8.5, 1.4 Hz, 2H, 
H-2‘, H-6‘), 7.7 (dd, J = 8.2, 4.6 Hz, 1H, H-6), 7.52-7.38 (m, 3H, H-3‘, H-4‘, H-5‘), 
5.23 (s, 2H, NCH2), 4.31 (q, J = 7.1 Hz, 2H, OCH2), 1.32 (t, J = 7.1 Hz, 3H, CH3). 
13
C NMR ppm: 167.2(s), 161.9(s), 156.5(s), 151.7(d), 137.1(s), 134.4(d), 134.0(s), 
133.5(s), 130.5(s), 128.6(d), 127.7(d), 125.7(d), 122.3(s), 121.3(d), 112.19(s), 
64.1(t), 61.8(t), 14.2(q).  
Anal. Calcd. for C20H15N5O3S: C, 59.25; H, 3.73; N, 17.27; S, 7.91; found: C, 59.28; 
H, 3.72; N, 17.30; S, 7.89. 
 
Further elution with dichloromethane/ethyl acetate 95:5 as eluant gave ethyl [3-
phenyl-5-oxopyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-4-yl]-
acetate (42). Yield 42%, mp 194.4-196.0°C. 
1
H NMR (CDCl3) ppm: 8.89 (dd, J = 
8.1, 1.5 Hz, 1H, H-8), 8.73 (dd, J = 4.6, 1.5 Hz, 1H, H-10), 8.37 (dd, J = 8.4, 1.2 Hz, 
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2H, H-2‘, H-6‘), 7.7 (dd, J = 8.1, 4.6 Hz, 1H, H-9), 7.52-7.38 (m, 3H, H-3‘, H-4‘, 
H-5‘), 5.23 (s, 2H, NCH2), 4.31 (q, J = 7.2 Hz, 2H, OCH2), 1.32 (t, J = 7.2 Hz, 3H, 
CH3). 
13
C NMR ppm: 167.7(s), 162.5(s), 156.8(s), 150.7(d), 135.1(s), 134.7(d), 
133.0(s), 133.8(s), 131.5(s), 128.2(d), 127.4(d), 125.9(d), 122.2(s), 121.3(d), 
111.81(s), 64.5(t), 60.8(t), 14.7(q).  
Anal. Calcd. for C20H15N5O3S: C, 59.25; H, 3.73; N, 17.27; S, 7.91; found: C, 59.27; 
H, 3.75; N, 17.28; S, 7.88. 
 
Further eluation with dichloromethane/ethyl acetate 9:1 as eluant gave [3’-phenyl-
5’-oxopyrido[3’,2’:4,5]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-4-yl]pent-2-
enedioic acid diethyl ester (43). Yield 30%, mp 201.6-203.5°C. 
1
H NMR ppm: 8.8 
(dd, J = 4.5, 1.0 Hz, 1H, H-8‘), 8.47 (dd, J = 8.0, 1.0 Hz, 1H, H-10‘), 7.89 (dd, J = 
6.9, 3.3 Hz, 2H, H-2‖, H-6‖), 7.48-7.43 (m, 4H, H-9‘, H-3‖, H-4‖, H-5‖), 6.87 (s, 
1H, CH), 4.67 (s, 2H, CH2), 4.20-4.34 (m, 4H, 2xCH2CH3), 1.21-1.36 (m, 6H, 
2xCH2CH3). 
13
C NMR ppm: 168.3(s), 165.5(s), 162.9(s), 155.2(s), 151.4(d), 
150.1(d), 142.2(s), 141.7(s), 132.8(d), 132.3(s), 129.1(s), 128.9(s), 128.5(d), 
127.9(d), 122.8(s), 120.5(d), 99.9(s), 77.2(d), 63.2(t), 61.7(t), 58.4(t), 14.2(q), 
14.1(q).  
Anal. Calcd. for C24H19N5O4S: C, 60.88; H, 4.04; N, 14.79; S, 6.77; found: C, 60.87; 
H, 4.07; N, 14.74; S, 6.75. 
 
N-(3-Acetylphenyl)-methanesulfonamide (48) 
According to the literature procedure [63], to a solution of 3-aminoacetophenone 50 
(1.0 g, 7.4 mmol) in absolute DCM (30 mL), pyridine(3 mL, 37.3 mmol) and 
methanesulfonyl chloride (0.86 mL, 11.2 mmol) were added. The reaction mixture 
was stirred at room temperature for 3h. The solution was washed with 6N HCl and 
the organic layer was dried over sodium sulfate, evaporated to dryness. The residue 
was purified by recrystallization from ethanol. Yield 100%, mp 189°C. 
1
H NMR 
ppm: 7.86 (t, 1H, H-4), 7.76 (dt, J = 7.5, 1.4 Hz, 1H, H-5), 7.59 (t, 1H, H-6), 7.48 (d, 
J = 7.5 Hz, 1H, H-2), 3.06 (s, 3H, SO2CH3), 2.63 (s, 3H, COCH3). 
13
C NMR ppm: 
197.95(s), 138.35(s), 137.68 (s), 130.06 (d), 125.25 (d), 125.15 (d), 120.09 (d), 39.59 
(q), 36.76 (q). 
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General Procedure for the Preparation of Chalcones 47 
To a solution of  N-(3-acetylphenyl)-methanesulfonamide 48 (1.0 g, 4.7 mmol) and 
appropriately substituted aldehyde 49 (4.7 mmol) in ethanol (10 mL), an aqueous 
solution of NaOH (14.1 mmol) was added dropwise. The reaction mixture was 
stirred at room temperature for 3h. After acidification with acetic acid at 0°C, the 
precipitate was filtered off and washed with water. The solid product was dried and 
recrystallized from ethanol to give 47a-l. 
 
N-{3-[(2E)-3-(2-Chlorophenyl)prop-2-enoyl]phenyl}methanesulfonamide (47a) 
White powder (100%), mp 142.2-142.7°C. 
1
H NMR (CDCl3) ppm: 8.21 (d, J = 15.7 
Hz, 1H, COCH=CH), 7.88-7.74 (m, 4H, H-4, H-5, H-3‘, H-6‘), 7.62-7.31 (m, 4H, H-
2, H-6, H-4‘, H-5‘), 7.46 (d, 1H, J = 15.7 Hz, 1H, CH=CH), 3.08 (s, 3H, SO2CH3). 
13
C NMR ppm: 167.0(s), 141.6(d), 137.6(s), 135.6(s), 132.9(s), 131.5(d), 130.3(d), 
130.1(d), 127.9(d), 127.1(d), 126.5(s), 125.3(d), 124.8(d), 124.2(d), 120.4(d), 
39.7(q). 
Anal. Calcd.for C16H14ClNO3S: C, 57.23; H, 4.20; Cl, 10.56; N, 4.17; S, 9.55; found 
C, 57.25; H, 4.25; Cl, 10.55; N, 4.13; S, 9.50. 
 
N-{3-[(2E)-3-(4-Dimethylaminophenyl)prop-2-enoyl]phenyl}methanesulfon-
amide (47b) 
Red solid (80%), mp 208.8-209.6°C. 
1
H NMR ppm: 9.98 (s, 1H, NH), 7.89-7.83 (m, 
2H, H-4, COCH=CH), 7.74-7.48 (m, 3H, CH=CH, H-5, H-6), 7.66 (s, 1H, H-2), 7.54 
(d, J = 8.2 Hz, 2H, H-2‘, H-6‘), 6.75 (d, J = 8.2 Hz, 2H, H-3‘, H-5‘), 3.04 (s, 3H, 
SO2CH3), 3.01 (s, 6H, NCH3).
 13
C NMR ppm: 188.3(s), 152.0(s), 145.4(d), 139.4(s), 
138.9(s), 130.7(d), 129.6(d), 123.7(d), 123.4(d), 121.8(s), 118.8(d), 115.9(d), 
111.7(d), 39.6(q), 39.3(q).  
Anal. Calcd. for C18H20N2O3S: C, 62.77; H, 5.85; N, 8.13; S, 9.31; found: C, 62.79; 
H, 5.80; N, 8.18; S, 9.33. 
 
N-{3-[(2E)-3-(3-Fluorophenyl)prop-2-enoyl]phenyl}methanesulfonamide (47c) 
mp 176.9-177.7°C.
1
H NMR ppm: 8.0 (dt, J = 6.4, 1.8 Hz, 1H, H-4), 7.87-7.68 (m, 
5H, COCH=CH, CH=CH, H-2‘, H-6‘, H-5), 7.54 (dd, J = 7.8 Hz,1H, H-4‘), 7.53 (s, 
1H, H-2), 7.52 (d, J =7.8 Hz, 1H, H-5‘), 7.30 (td, J = 1.8, 8.3 Hz, 1H, H-6), 3.03 (s, 
3H, SO2CH3). 
13
C NMR ppm: 188.8(s), 160.0(s), 142.7(d), 139.4(s), 138.3(s), 
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137.2(s), 130.9(d), 129.7(d), 125.4(d), 124.1(d), 124.0(d), 123.5(d), 119.0(d), 
117.1(d, JC-F=133.8 Hz), 114.8(d), 39.4(q).  
Anal. Calcd. for C16H14FNO3S: C, 60.18; H, 4.42; N, 4.39; S, 10.04; found: C, 60.13; 
H, 4.45; N, 4.42; S, 10.08. 
 
N-{3-[1-Acetyl-3-(2-methoxyphenyl)prop-2-enoyl]phenyl}methanesulfonamide 
(47d) 
Yellow solid (95%), mp 147.3-148.4°C. 
1
H NMR ppm: 8.03 (d, J = 15.8 Hz, 1H, 
COCH=CH), 7.94-7.85 (m, 3H, H-4, H-5, H-6‘), 7.81 (d, J = 15.8 Hz, 1H, CH=CH), 
7.59-7.43 (m, 3H, H-2, H-6, H-4‘), 7.15-7.01 (m, 2H, H-3‘, H-5‘), 3.91 (s, 3H, 
OCH3), 3.04 (s, 3H, SO2CH3). 
13
C NMR ppm: 189.0(s), 158.3(s), 139.3(s), 138.9(d), 
138.7(s), 132.4(d), 129.7(d), 128.8(d), 123.8(d), 123.7(d), 122.7(s), 121.9(d), 
120.7(d), 118.8(d), 111.8(d), 55.7(q), 39.4(q). 
Anal. Calcd. for C17H17NO4S: C, 61.61; H, 5.17; N, 4.23; S, 9.68; found: C, 61.62; 
H, 5.17; N, 4.22; S, 9.63. 
 
N-{3-[1-Acetyl-3-(3,4-dimethoxyphenyl)prop-2-enoyl]phenyl}methanesulfon-
amide (47e) 
Yellow solid (95%), mp 182.3-183.7.2°C. 
1
H NMR ppm: 7.96 (dt, J = 5.1, 1.7 Hz, 
1H, H-5), 7.85-7.48 (m, 4H, H-5‘, H-6‘, COCH=CH, CH=CH), 7.73 (s, 2H, H-2), 
7.52(s, 1H, H-2‘), 7.40 (dd, J = 8.3 Hz, 1.7 Hz, 1H, H-4), 7.04 (d, J = 8.3 Hz, 1H, 
H-6), 3.87 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.05 (s, 3H, SO2CH3). 
13
C NMR ppm: 
189.0(s), 158.3(s), 139.3(s), 138.9(d), 138.7(s), 132.4(d), 129.7(d), 128.8(s), 
123.8(d), 123.7(d), 122.7(s), 121.9(d), 120.7(d), 118.8(d), 111.8(d), 55.7(q), 39.4(q). 
Anal. Calcd. for C18H19NO5S: C, 59.82; H, 5.30; N, 3.88; S, 8.87; found: C, 59.88; 
H, 5.35; N, 3.83; S, 8.92. 
 
N-{3-[(2E)-3-(4-Methoxyphenyl)prop-2-enoyl]phenyl}methanesulfonamide (47f) 
Yellow solid (80%), mp 196.3-197.2°C. 
1
H NMR ppm: 9.99 (s, 1H, NH), 7.97-7.92 
(dt, J = 6.8, 1.5 Hz, 1H, H-5), 7.86 (d, J = 1.5 Hz, 1H, H-4) 7.85 (d, J = 8.7 Hz, 2H, 
H-2‘, H-6‘), 7.72 (s, 1H, H-2), 7.59-7.47 (m, 3H, COCH=CH, CH=CH, H-6), 7.04 
(d, J = 8.7 Hz, 2H, H-3‘, H-5‘), 3.83 (s, 3H, OCH3), 3.06 (s, 3H, SO2CH3). 
13
C NMR 
ppm: 188.7(s), 161.4(s), 144.3(d), 138.9(s), 138.8(s), 130.7(d), 129.7(d), 127.1(s), 
124.0(d), 123.8(d), 119.4(d), 118.8(d), 114.4(d), 55.3(q), 39.4(q). 
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Anal. Calcd. for C17H17NO4S: C, 61.61; H, 5.17; N, 4.23; S, 9.68; found: C, 61.63; 
H, 5.14; N, 4.24; S, 9.64. 
 
N-{3-[(2E)-3-(4-Hydroxyphenyl)prop-2-enoyl]phenyl}methanesulfonamide (47g) 
Yellow solid (80%), mp 187.7-189.2°C. 
1
H NMR ppm: 9.73 (s, 1H, NH), 7.81 (dd, J 
= 5.5, 1.6 Hz, 2H, H-4, H-6), 7.72-7.61 (m, 4H, H-2, COCH=CH, H-3‘, H-2‘), 7.53-
7.41 (m, 2H, CH=CH, H-5), 6.86 (dd, J = 6.4, 1.6 Hz, 1H, H-6), 4,33 (s, 1H, OH), 
2.99 (s, 3H, SO2CH3).
 13
C NMR ppm: 188.8(s), 160.8(s), 144.7(d), 140.4(s), 
138.9(s), 130.9(d), 129.5(d), 125.2(s), 123.7(d), 122.7(d), 119.0(d), 118.1(d), 
115.9(d), 39.4(q).  
Anal. Calcd. For C16H15NO4S: C, 60.55; H, 4.76; N, 4.41; S, 10.10; found: C, 60.56; 
H, 4.78; N, 4.45; S, 10.12. 
 
N-(3-{(2E)-3-(2-Hydroxy-3-methoxyphenyl)prop-2-enoyl}phenyl)methane 
sulfonamide (47h) 
mp 292-294.2°C. 
1
H NMR ppm: 9.83 (s, 1H, NH), 8.08 (d, J = 15.8 Hz, 1H, 
COCH=CH), 7.89-7.84 (m, 2H, H-4‘, H-6‘), 7.74 (d, J = 15.8 Hz, 1H, CH=CH), 7.54 
(dd, J = 6.7 Hz, 1H, H-5‘), 7.50 (s, 1H, H-2), 7.44 (dd, J = 8.0, 1.2 Hz, H-6), 7.05 
(dd, J = 8.0, 1.2 Hz, 1H, H-4), 6.85 (t, J = 8.0 Hz, 1H, H-5), 3.85 (s, 3H, OCH3), 3.05 
(s, 3H, SO2CH3).
 13
C NMR ppm: 189.1(s), 148.0(s), 146.6(s), 139.6(d), 138.9(s), 
129.8(d), 123.8(d), 121.4(s), 123.7(d), 121.1(d), 119.8(d), 119.1(d), 
118.8(d),113.6(d), 55.9(q), 39.4 (q). 
Anal. Calcd. for C17H17NO5S: C, 58.78; H, 4.93; N, 4.03; S, 9.23; found: C, 58.81; 
H, 4.95; N, 4.01; O, 23.06; S, 9.25. 
 
N-{3-[(2E)-3-(3-Methoxyphenyl)prop-2-enoyl]phenyl}methanesulfonamide (47i) 
mp 140.5-140.5°C. 
1
H NMR ppm: 7.92 (dt, J = 1.9, 5.2 Hz, H, H-4), 7.85 (s, 1H, 
H-2), 7.79 (dd, J = 14.5 Hz, 1H, COCH=CH), 7.58-7.34 (m, 5H, H-5, H-3‘, H-4‘, 
H-5‘, H-6‘), 7.47 (dd, J = 14.5 Hz, 1H, CH=CH), 7.04 (dt, J = 1.9, 7.4 Hz, 1H, H-6), 
7.05 (dt, J = 7.2, 5.2 Hz, 1H, H-5), 3.84 (s, 3H, OCH3), 3.00 (s, 3H, SO2CH3). 
13
C 
NMR ppm: 189.0(s), 159.6(s), 144.1(d), 139.8(s), 138.5(s), 135.9(s), 129.9(d), 
129.7(d), 124.0(d), 123.6(d), 122.4(d), 121.5(d), 118.9(d), 116.7(d), 113.4(d), 
55.2(q), 39.4(q). 
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Anal. Calcd. for C17H17NO4S: C, 61.61; H, 5.17; N, 4.23; S, 9.68; found: C, 61.62; 
H, 5.12; N, 4.26; S, 9.69. 
 
N-(3-{(2E)-3-[4-(Diethylamino)phenyl]prop-2-enoyl}phenyl)methanesulfon-
amide (47j) 
Orange solid (85%), mp 170.2-170.9°C. 
1
H NMR ppm: 9.63 (s, 1H, NH), 7.89-7.83 
(m, 3H, H-4, H-5, COCH=CH), 7.68 (s, 1H, H-2), 7.48 (m, 2H, H-6, CH=CH), 7.5 
(d, J = 8.4 Hz, 2H, H-2‘, H-6‘), 6.70 (dd, J = 8.4 Hz. 2H, H-3‘, H-5‘), 3.41 (q, J = 3.7 
Hz, 4H, CH2CH3), 3.04 (s, 3H, SO2CH3), 1.12 (t, J = 3.7 Hz, 6H, 2xCH2CH3).
 13
C 
NMR ppm: 188.2(s), 149.5(s), 145.5(d), 139.5(s), 139.0(s), 131.1(d), 129.6(d), 
123.5(d), 123.3(d), 121.0(s), 118.8(d), 115.3(d), 111.1(d), 43.7(t), 39.3(q), 12.4(q).  
Anal. Calcd. for C20H24N2O3S: C, 64.49; H, 6.49; N, 7.52; S, 8.61; found: C, 64.43; 
H, 6.44; N, 7.57; S, 8.65. 
 
N-{3-[(2E)-3-(2-Bromophenyl)prop-2-enoyl]phenyl}methanesulfonamide (47k) 
White powder (92%), mp 153°C. 
1
H NMR ppm: 10.03 (s, 1H, NH), 8.17 (dd, J = 7.8, 
1.6 Hz, 1H, H-3‘), 8.06-7.84 (m, 4H, CH=CH, COCH=CH, H-4, H-5), 7.76 (dd, J = 
7.8, 1.2 Hz, 1H, H-5‘), 7.62-7.37 (m, 4H, H-2, H-6), 7.50 (dd, J = 7.4, 1.2 Hz, 1H, 
H-6‘), 7.38 (dd, J = 7.6, 1.7 Hz, 1H, H-4‘), 3.06 (s, 3H, SO2CH3). 
13
C NMR ppm: 
188.6(s), 141.4(d), 139.0(s), 138.2(s), 133.8(s), 133.3(d), 132.2(d), 129.8(d), 
128.6(d), 128.25(d), 125.3(s), 124.8(d), 124.3(d), 124.2(d), 118.8 (d), 39.4 (q).  
Anal. Calcd. for C16H14BrNO3S: C, 50.54; H, 3.71; Br, 21.01; N, 3.68; S, 8.43; 
found: C, 50.59; H, 3.77; Br, 21.03; N, 3.67; S, 8.44. 
 
N-{3-[1-Acetyl-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]phenyl}methanesulfon-
amide (47l) 
White solid (95%), mp 195.3-196.2°C. 
1
H NMR ppm 8.13 (d, J = 1.6 Hz, 1H, H-4), 
7.96. (d, J = 15.6 Hz, 1H, COCH=CH), 7.71 (dd, J = 1.6, 8.0 Hz, 1H, H-5), 7.55 (s, 
1H, H-2‘), 7.44 (d, J = 8.0 Hz, 1H, H-6), 7.43 (d, J = 15.6 Hz, 1H, CH=CH), 6.96 (s, 
2H, H-2‘, H-6‘), 3.94 (s, 6H, 2xOCH3), 3.91 (s, 3H, OCH3), 3.07 (s, 3H, SO2CH3). 
13
C NMR ppm: 190.0(s), 153.5(s), 146.9(d), 140.8(s), 139.3(s), 138.3(s), 130.0(s), 
129.9(d), 124.9(d), 124.4(d), 120.6(d), 119.9(d), 106.0(d), 61.0(q),56.2(q), 39.6(q). 
Anal. Calcd. for C19H21NO6S: C, 58.30; H, 5.41; N, 3.58; S, 8.19; found: C, 58.33; 
H, 5.46; N, 3.63; S, 8.17. 
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General Procedure for the Preparation of 4,5 Dihydropyrazoles 
According to the literature procedure [64], the chalcone (1 mmol) was dissolved in 
acetic acid (15 mL) and hydrazine hydrate (5 mmol) was added. The solution was 
stirred at reflux overnight. The reaction mixture was cooled to room temperature and 
poured over crushed ice (50 mL). The precipitate was filtered off and washed with 
water. The solid product was dried and recrystallized from ethanol to give 45a-l. 
 
N-{3-[1-Acetyl-3-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methane sulfonamide (45a) 
White solid (84%), mp 250.3-251.4°C. 
1
H NMR ppm: 9.87 (s, 1H, NH), 7.66 (s, 1H, 
H-2), 7.52-7.28 (m, 6H, H-4, H-5; H-6, H-3‘‘, H-4‘‘, H-6‘‘), 7.07 (dd, J = 3.8, 4.0 
Hz, 1H, H-5‘‘), 5.77 (dd, J = 11.8 Hz, 4.8 Hz, H-5‘), 3.95 (dd, J = 11.8, 17.9 Hz, 1H, 
H-4‘), 3.02 (dd, J = 4.8, 17.9 Hz, 1H, H-4‘), 3.01 (s, 3H, SO2CH3), 2.36 (s, 3H, 
COCH3). 
13
C NMR ppm: 167.2(s), 158.3(s), 153.6(s), 138.8(s), 134.3(s), 132.1 (s), 
129.8(d), 129.6 (d), 128.9 (d), 127.6(d), 126.2(d), 122.3(d), 121.4(d), 117.1 (d), 
40.9(t), 39.3(q), 21.6(q) . 
Anal. Calcd. for C18H18ClN3O3S C, 55.17; H, 4.63; Cl, 9.05; N, 10.72; O, 12.25; S, 
8.18; found C, 55.13; H, 4.66; Cl, 9.09; N, 10.71; O, 12.28, S, 8.15. 
 
N-{3-[1-Acetyl-3-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45c) 
White solid (85%), mp 216.8-217.4°C. 
1
H NMR ppm: 9.93 (s, 1H, NH), 7.67(s, 1H, 
H-2), 7.43 (s, 1H, H-2‘‘), 7.40-7.31 (m, 3H, H-4, H-5, H-6), 7.12-7.02 (m, 3H, H-4‘‘, 
H-5‘‘, H-6‘‘), 5.57 (dd, J = 11.9, 4.8 Hz, 1H, H-5‘), 3.86 (dd, J =11.9, 18.0 Hz, 1H, 
H-4‘), 3.04 (dd, J = 4.8, 18.0 Hz, 1H, H-4‘), 3.01 (s, 3H, SO2CH3), 2.30 (s, 3H, 
COCH3). 
13
C NMR ppm: 168.0(s), 154.1(s), 145.4(s), 139.2(s), 130.7(d), 129.7(d), 
122.3(d), 121.8 (s), 121.4(d), 117.1 (d, JC-F = 77.9 Hz), 114.2 (d), 113.7(d), 112.6(d), 
112.2 (d), 59.0(q), 41.9(t), 39.6(q), 21.6(q) . 
Anal. Calcd. for C18H18FN3O3S: C, 57.59; H, 4.83; N, 11.19; S, 8.54; found: C, 
57.57; H, 4.87; N, 11.21; S, 8.59. 
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N-{3-[1-Acetyl-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45d) 
White solid (91%), mp 226.8-227.4°C. 
1
H NMR ppm 9.93 (s, 1H, NH), 7.64(s, 1H, 
H-2), 7.48-7.21 (m, 4H, H-4, H-5, H-6, H-3‘‘), 7.06-6.83 (m, 3H, H-4‘‘, H-5‘‘, H-
6‘‘), 5.67 (dd, J = 11.8, 4.4 Hz, 1H, H-5‘), 3.83 (dd, J =11.8, 17.7 Hz, 1H, H-4‘), 
3.82 (s, 3H, OCH3) 3.01 (s, 3H, SO2CH3), 2.91 (dd, J = 4.4, 17.7 Hz, 1H, H-4‘), 2.34 
(s, 3H, COCH3). 
13
C NMR ppm: 167.3(s), 155.6(s), 154.2(s), 138.7(s), 132.2(s), 
129.7(d), 129.1(s), 128.4(d), 125.1(d), 122.2 (d), 121.4(d), 120.2 (d), 117.0 (d), 
111.2(d), 55.5 (q), 55.1(d), 41.1(t), 39.3(q), 21.6(q) . 
Anal. Calcd. for C19H21N3O4S: C, 58.90; H, 5.46; N, 10.85; S, 8.28; found: C, 58.93; 
H, 5.44; N, 10.89; S, 8.30. 
 
N-{3-[1-Acetyl-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45e) 
White solid (93%), mp 209.1-209.8°C. 
1
H NMR ppm: 9.88 (s, 1H, NH), 7.66(s, 1H, 
H-2), 7.51-7.38 (m, 2H, H-4, H-6), 7.32 (dt, J = 7.3, 2.0 Hz,1H, H-5), 6.88 (d, J = 8.3 
Hz, 1H, H-2‘‘), 6.80 (d, J = 1.9 Hz, 1H, H-5‘‘), 6.65 (dd, J = 8.3, 1.9 Hz, 1H, H-6‖), 
5.49 (dd, J = 11.7, 4.4 Hz, 1H, H-5),  3.81 (dd, J = 11.7, 17.9 Hz, 1H, H-4‘), 3.72 (s, 
3H, OCH3), 3.71(s, 3H, OCH3), 3.07 (dd, J = 4.4, 17.9 Hz, 1H, H-4‘), 3.02 (s, 3H, 
SO2CH3), 2.30 (s, 3H, COCH3). 
13
C NMR ppm: 167.4(s), 153.7(s), 148.7(s), 
147.9(s), 138.8(s), 134.7(s), 132.2(s), 129.8(d), 122.3 (d), 121.2(d), 117.1 (d), 
117.0(d), 111.9(d), 109.6(d), 59.2(d), 55.5(q), 55.4(q), 42.1(t), 39.4(q), 21.7(q) . 
Anal. Calcd. for C20H23N3O5S: C, 57.54; H, 5.55; N, 10.07; S, 7.68; found: C, 57.53; 
H, 5.59; N, 10.07; S, 7.69. 
 
N-{3-[1-Acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45f) 
White solid (90%), mp 205.1-205.8°C. 
1
H NMR ppm: 9.90 (s, 1H, NH), 7.66(s, 1H, 
H-2), 7.50-7.39 (m, 2H, H-4, H-6), 7.33 (dt, J = 7.1, 1.9 Hz, 1H, H-5), 7.11 (d, J = 
8.7 Hz, 2H, H-2‘‘, H-6‘‘), 6.87 (d, J = 8.7 Hz, 2H, H-3‘‘, H-5‘‘), 5.49 (dd, J = 12.0, 
4.6 Hz, 1H, H-5‘), 3.84 (dd, J = 12.0, 17.0 Hz, 1H, H-4‘), 3.73(s, 3H, OCH3), 3.09 
(dd, J = 4.6, 17.0 Hz, 1H, H-4‘), 3.02 (s, 3H, SO2CH3), 2.29 (s, 3H, COCH3). 
13
C 
NMR ppm: 167.2(s), 158.3(s), 153.6(s), 138.8(s), 134.3(s), 132.1 (s), 129.8(d), 126.7 
(d), 122.3 (d), 121.2(d), 117.0(d), 113.9(d), 79.0(d), 55.0(q), 42.0(t), 39.4(q), 21.6(q).  
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Anal. Calcd. for C19H21N3O4S: C, 58.90; H, 5.46; N, 10.85; S, 8.28; found: C, 58.93; 
H, 5.47; N, 10.89; S, 8.24. 
 
N-{3-[1-Acetyl-3-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45g) 
White solid (81%), mp 233.5-233.8°C. 
1
H NMR ppm: 9.77 (s, 1H, NH), 9.45 (s, 1H, 
OH), 7.66 (s, 1H, H-2), 7.45-7.33 (m, 3H, H-4, H-5, H-6), 6.98 (d, J = 7.9 Hz, 2H, 
H-2‘‘, H-6‘‘), 6.70 (d, J = 7.9 Hz, 2H, H-3‘‘, H-5‘‘), 5.42 (dd, J = 11.9, 4.1 Hz, 1H, 
H-5‘), 3.79 (dd, J = 11.9, 17.6 Hz, 1H, H-4‘), 3.03 (dd, J = 4.1, 17.6 Hz, 1H, H-4‘), 
3.02 (s, 3H, SO2CH3), 2.28 (s, 3H, COCH3). 
13
C NMR ppm: 167.2(s), 156.5(s), 
153.6 (s), 138.8(s), 132.6(s), 132.2(s),129.8(d), 126.6 (d), 122.2 (d), 121.2(d), 
117.1(d), 115.2(d),  58.9(d), 42.0(t), 39.4(q), 21.7(q). 
Anal. Calcd. for C18H19N3O4S: C, 57.89; H, 5.13; N, 11.25; S, 8.59; found: C, 57.86; 
H, 5.10; N, 11.28; S, 8.54. 
 
N-{3-[1-Acetyl-3-(2-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-
yl]phenyl}methanesulfonamide (45h) 
White solid (87%), mp 242.8-243.4°C. 
1
H NMR ppm: 9.87 (s, 1H, NH), 8.89 (s, 1H, 
OH), 7.66(s, 1H, H-2), 7.44-7.28 (m, 3H, H-4, H-5, H-6), 6.85 (d, J = 7.6 Hz, 1H, H-
6‘‘), 6.69 (t, J = 7.6 Hz, 1H, H-5‘‘), 6.46 (d, J = 7.6 Hz, 1H, H-4‖), 5.66 (dd, J = 
11.6, 4.1 Hz, 1H, H-5‘), 3.79 (s, 4H, OCH3), 3.77 (dd, J = 11.6, 17.9 Hz, 1H, H-4‘), 
3.02 (s, 3H, SO2CH3), 2.88 (dd, J = 4.1, 17.9 Hz, 1H, H-4‘), 2.32 (s, 3H, COCH3). 
13
C NMR ppm: 171.2(s), 166.1(s), 153.8(s), 140.2(s), 138.5(s), 130.9(s), 129.7 (d), 
128.2(s), 126.1(s), 122.1(d), 121.1(d), 118.7 (d), 117.3 (d), 117.1(d), 110.6(d), 
55.8(q), 55.3(d), 41.0(t), 39.7(q), 21.6(q) . 
Anal. Calcd. for C19H21N3O5S: C, 56.56; H, 5.25; N, 10.42; S, 7.95; found: C, 56.60; 
H, 5.28; N, 10.47; S, 7.99. 
 
N-{3-[1-Acetyl-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45i) 
White solid (88%), mp 207.9-208.5°C. 
1
H NMR ppm: 9.90 (s, 1H, NH), 7.66(s, 1H, 
H-2), 7.46 (s, 1H, H-2‘‘), 7.42-7.21 (m, 3H, H-5, H-6, H-5‘‘), 6.84-6.74 (m, 3H, H-4, 
H-4‘‘, H-6‘‘), 5.52 (dd, J = 4.6, 12.0 Hz, 1H, H-5), 3.83 (dd, J = 12.0, 17.9 Hz, 1H, 
H-4), 3.37 (s, 3H, OCH3), 3.04 (dd, J = 4.6, 17.9 Hz, 1H, H-4), 3.02 (s, 3H, 
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SO2CH3), 2.32 (s, 3H, COCH3). 
13
C NMR ppm: 171.9(s), 167.5(s), 153.7(s), 
140.3(s), 138.8(s), 132.9 (d), 131.9(s), 129.8 (d), 129.2 (d), 128.2(d), 126.1(d), 
122.3(d), 121.4(d), 120.8 (s), 117.3 (d), 59.3(d), 55.3(q), 41.1(t), 39.4(q), 21.5(q) . 
Anal. Calcd. for C19H21N3O4S: C, 58.90; H, 5.46; N, 10.85; S, 8.28; found: C, 58.94; 
H, 5.43; N, 10.86; S, 8.24. 
 
N-{3-[1-Acetyl-3-(4-diethylaminophenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl} 
methanesulfonamide (45j) 
White solid (89%), mp 205.1-205.4°C. 
1
H NMR ppm: 9.93 (s, 1H, NH), 7.66(s, 1H, 
H-2), 7.46-7.30 (m, 3H, H-4, H-5, H-6), 6.96 (d, J = 8.6 Hz, 2H, H-2‘‘, H-6‘‘), 6.57 
(d, J = 8.6 Hz, 2H, H-3‘‘, H-5‘‘), 5.41 (dd, J = 11.6, 4.1 Hz,1H, H-5‘), 3.77 (dd, J = 
11.6, 17.9 Hz, 1H, H-4‘), 3.28 (q, J = 6.9 Hz, 4H, NCH2), 3.09 (dd, J = 4.1, 17.9 Hz, 
1H, H-4‘), 3.02 (s, 3H, SO2CH3), 2.27 (s, 3H, COCH3), 1.05 (t, J = 6.9 Hz, 6H, 
NCH2CH3). 
13
C NMR ppm: 167.1(s), 153.6(s), 146.5 (s), 138.8(s), 132.3(s), 
129.7(d),128.5(s), 126.5 (d), 122.5 (d), 121.1(d), 117.0(d), 111.1(d), 99.5 (d), 
59.0(q), 43.6 (t), 39.3(q), 12.4(q). 
Anal. Calcd for C22H28N4O3S: C, 61.66; H, 6.59; N, 13.07; S, 7.48; found: C, 61.67; 
H, 6.63; N, 13.09; S, 7.45. 
 
{3-[1-Acetyl-3-(2-bromophenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl}methane 
sulfonamide (45k) 
White solid (88%), mp 250.9-251.5°C. 
1
H NMR ppm: 9.89 (s, 1H, NH), 7.69 (d, J = 
0.8 Hz, H-3‘‘), 7.66 (s, 1H, H-2), 7.46 (dd, J = 1.6 Hz, 1H, H-4), 7.41-7.30 (m, 3H, 
H-3‘‘, H-5‘‘, H-6‘‘), 7.24 (dd, J = 1.6, 7.6 Hz, 1H, H-5), 7.19 (d, J = 7.6 Hz, 1H, 
H-6), 7.04 (dd, J = 1.3, 7.4 Hz, 1H, H-4‘‘), 5.72 (dd, J = 4.6, 12.0 Hz, 1H, H-5), 3.98 
(dd, J = 12.0, 17.9 Hz, 1H, H-4‘), 3.96 (dd, J = 4.6, 17.9 Hz, 1H, H-4‘), 3.02 (s, 3H, 
SO2CH3), 2.38 (s, 3H, COCH3). 
13
C NMR ppm: 167.5(s), 153.7(s), 140.3(s), 
138.8(s), 132.9 (d), 131.9(s), 129.8 (d), 129.2 (d), 128.2(d), 126.1(d), 122.3(d), 
121.4(d), 120.8 (s), 117.3 (d), 59.4(d), 41.1(t), 39.4(q), 21.5(q). 
Anal. Calcd. for C18H18BrN3O3S: C, 49.55; H, 4.16; Br, 18.31; N, 9.63; S, 7.35; 
found: C, 49.50; H, 4.12; Br, 18.35; N, 9.62; S, 7.36. 
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N-{3-[3-(2-Chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenyl}methansulfon-
amide (51) 
The chalcone 47a (1 mmol) was dissolved in absolute ethanol (25 mL), and 
hydrazine hydrate (1 mmol) and piperidine (0.10 mL) were added. The solution 
stirred at reflux overnight. The reaction mixture was poured over crushed ice (50 
mL) and the precipitate was filtered off and washed with water. The solid product 
was dried and recrystallized from ethanol to give 51 (yield 20%), mp 250.3-251.4°C. 
1
H NMR ppm: 9.81 (s, 1H, NH), 7.72 (s, 1H, H-2), 7.58-7.15 (m, 7H, H-4, H-5, H-6, 
H-3‘‘, H-4‘‘, H-5‘‘, H-6‘‘), 7.15 (s, 1H, NH),5.13 (dd, J = 9.8, 11.4 Hz, 1H, H-5‘), 
3.55 (dd, J = 11.4, 16.4 Hz 1H, H-4‘), 3.01 (s, 3H, SO2CH3), 2.71 (dd, J = 9.8, 16.4 
Hz, 1H, H-4‘).13C NMR ppm: 167.2(s), 158.3(s), 153.6(s), 138.8(s), 134.3(s), 132.1 
(s), 129.4(d), 129.3 (d), 128.8 (d), 127.6(d), 126.4(d), 121.1(d), 119.4(d), 116.1 (d), 
60.4(t), 39.3(q). 
Anal. Calcd. for C16H16ClN3O2S: C, 54.93; H, 4.61; Cl, 10.13; N, 12.01; S, 9.17; 
found: C, 54.98; H, 4.64; Cl, 10.17; N, 12.04; S, 9.21. 
 
General Procedure for the Preparation of 2-amino-3-cyanopyridine 
Method 1: Malononitrile (1.5 mmol) and ammonium acetate (12 mmol) were added 
to a stirred solution of appropriate chalcone (1.5 mmol) in absolute ethanol (5 mL). 
The reaction mixture was heated under reflux for 16 h and then concentrated at 
reduced pressure. The solid product was purified by column chromatography using 
dichoromethane/ethyl acetate as eluant. 
Method 2: The opportune benzaldehyde (4.7 mmol) and malononitrile (4.7 mmol) in 
5 mL of absolute dioxane were stirred to room temperature for 15 min. The mixture 
was added dropwise to a suspension of 48 (4.7 mmol) and ammonium acetate (7 
mmol) in absolute dioxane (5 mL). The reaction was heated at reflux overnight, 
cooled at room temperature and then evaporated under reduced pressure. The crude 
product was purified by column chromatography using dichoromethane/ethyl acetate 
as eluant. 
 
N-{3-[6-Amino-4-(2-chloro-phenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46a) 
White solid (94%), mp 172.5-173.1°C. 
1
H NMR ppm: 9.86 (s, 1H, NH), 7.89-7.80 
(m, 2H, H-3‘‘, H-5‘‘), 7.78-7.15 (m, 5H, H-3, H-4, H-5, H-2‘‘, H-6‘‘), 7.52 (s, 1H, 
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H-3‘), 7.15 (bs, 2H, NH2), 7.11 (s, 1H, H-2), 3.02 (s, 3H, SO2CH3). 
13
C NMR ppm: 
160.0(s), 158.2(s), 153.0(s), 138.8(s), 138.7(s), 137.6 (s), 130.9(d), 130.5 (d), 130.0 
(d), 129.6(d), 127.5(d), 123.0(d), 121.8(d), 118.8(d), 115.8(s), 113.0(s), 109.9(d), 
88.7(s), 39.4(q). 
Anal. Calcd. for C19H15ClN4O2S: C, 57.21; H, 3.79; Cl, 8.89; N, 14.05; S, 8.04; 
found: C, 57.25; H, 3.83; Cl, 8.92; N, 14.08; S, 8.07. 
 
N-{3-[6-Amino-4-(4-dimethylamino-phenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46b) 
Violet solid (95%), mp 201.3-202.8°C. 
1
H NMR ppm: 9.95 (s, 1H, NH), 7.91-7.66 
(m, 4H, H-2, H-4, H-5, H-6), 7.55 (d, J=8.7Hz, 2H, H-3‘‘, H-5‘‘), 7.49 (s, 1H, H-3‘), 
6.75 (d, J = 8.7 Hz, 2H, H-2‘‘-H-6‘‘), 3.04 (s, 3H, SO2CH3), 3.02 (s, 6H, NCH3). 
13
C 
NMR ppm: 188.2(s), 152.0(s), 145.5(d), 139.4(s), 138.8.(s), 130.7(d), 129.6(d), 
123.7(d), 121.7(s), 118.8(d), 115.9(d), 111.7(d), 99.4 (s), 75.2(d), 39.6 (q), 39.3(q). 
Anal. Calcd. for C21H21N5O2S: C, 61.90; H, 5.19; N, 17.19; S, 7.87; found: C, 61.93; 
H, 5.15; N, 17.24; S, 7.85. 
 
N-{3-[6-Amino-4-(3-fluorophenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46c) 
White solid (90%), mp 168.1-168.8°C. 
1
H NMR ppm 9.86 (s, 1H, NH), 7.91(s, 1H, 
H-3‘), 7.86 (d, J = 7.7 Hz 1H, H-4‘‘), 7.7-7.33 (m, 5H, H-4, H-5, H-6, H-4‘‘, H-6‘‘), 
7.54 (s, 1H, H-2‘‘), 7.21 (s, 1H, H-2),7.11 (bs, 2H, NH2), 3.03 (s, 3H, SO2CH3). 
13
C 
NMR ppm: 164.4(s), 160.7(s), 159.5(s), 158.4(s), 153.4(s), 138.7 (s), 130.9 (d), 
130.7(d), 129.6(d), 124.5(d), 123.0(d), 121.6(d), 118.9(d), 115.1(d, JC-F = 77.1 Hz), 
109.4(d), 99.5(d), 86.8(s), 39.4(q). 
Anal. Calcd. for C19H15FN4O2S: C, 59.67; H, 3.95; N, 14.65; S, 8.38; found: C, 
59.62; H, 3.98; N, 14.61; S, 8.43. 
 
N-{3-[6-Amino-4-(2-methoxyphenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46d) 
Yellow solid (88%), mp 143.7-144.8°C. 
1
H NMR ppm: 9.86 (s, 1H, NH), 7.87 (s, 
1H, H-3‘), 7.79 (d, J = 7.6 Hz, 1H, H-4), 7.47 (dd, J = 8.3, 16.4 Hz, 2H, H-5‘‘, 
H-6‘‘), 7.33 (s, 1H, H-2),7.15 (dd, J = 8.3, 18.1 Hz, 1H, H-4‘‘), 7.11-7-05 (m, 3H, 
H-5, H-6, H-3‘‘), 7.06 (bs, 2H, NH2), 3.81 (s, 3H, OCH3), 3.02 (s, 3H, SO2CH3). 
13
C 
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NMR ppm: 160.0(s), 157.9(s), 155.9(s), 152.9(s), 138.8(s), 138.7(s), 130.9(d), 129.9 
(d), 129.9 (d), 125.9(s), 122.8(d), 121.4(d), 120.6(s), 118.6(d), 116.6(s), 111.7(d), 
110.4(d), 89.3(s), 55.4 (q), 39.4(q). 
Anal. Calcd. for C20H18N4O3S: C, 60.90; H, 4.60; N, 14.20; S, 8.13; found: C, 60.93; 
H, 4.68; N, 14.25; S, 8.14. 
 
N-{3-[6-Amino-4-(3,4-dimethoxyphenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46e) 
White solid (85%), mp 170.3-171.2°C.
1
H NMR ppm 10.05 (s, 1H, NH), 7.90-7.83 
(m, 2H, H-4, H-5), 7.51-7.11 (m, 3H, H-6, H-5‘‘, H-6‘‘), 7.47 (s, 1H, H-3‘), 7.28 (s, 
1H, H-2), 7.20 (s, 1H, H-2‘‘), 6.98 (bs, 2H, NH2), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, 
OCH3), 3.03 (s, 3H, SO2CH3). 
13
C NMR ppm: 160.8(s), 158.1(s), 154.7(s), 150.0(s), 
148.5(s), 139.0(s), 138.7(s), 129.5 (d), 129.0 (s), 122.9(d), 121.4(d), 120.9(d), 
118.8(d), 117.2(s), 111.9(d), 111.6(d), 109.3(d), 86.7(s), 55.6 (q), 39.4(q). 
Anal. Calcd. for C21H20N4O4S: C, 59.42; H, 4.75; N, 13.20; S, 7.55; found: C, 59.45; 
H, 4.79; N, 13.23; S, 7.58. 
 
N-{3-[6-Amino-4-(4-methoxy-phenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46f) 
White solid (92%), mp 164.5-165.1°C. 
1
H NMR ppm: 10.03 (s, 1H, NH), 8.11 (d, 
J=8.8 Hz, 2H, H-3‘‘, H-5‘‘), 7.56-7.32 (m, 3H, H-3, H-4, H-5), 7.47 (s, 1H, H-3‘), 
7.22 (s, 1H, H-2), 7.05 (d, J = 8.8 Hz, 2H, H-2‘‘-H-6‘‘), 7.00 (bs, 2H, NH2), 3.85 (s, 
3H, OCH3), 3.83 (s, 3H, OCH3), 3.10 (s, 3H, SO2CH3). 
13
C NMR ppm: 160.8(s), 
160.4(s), 158.1(s), 154.5(s), 138.9(s), 138.7(s), 129.7(d), 129.5 (d), 128.9 (s), 
122.9(d), 121.4(d), 118.7(d), 117.1(s), 114.1(d), 109.2(d), 86.6(s), 55.3 (q), 39.4(q). 
Anal. Calcd. for C20H18N4O3S: C, 60.90; H, 4.60; N, 14.20; S, 8.13; found: C, 60.96; 
H, 4.68; N, 14.24; S, 8.15. 
 
N-{3-[6-Amino-4-(4-hydroxyphenyl)-5-cyano-pyridin-2-yl]-phenyl}- 
methanesulfonamide (46g) 
White solid (84%), mp 222.8-223.9°C. 
1
H NMR ppm: 9.92 (bs, 2H, NH, OH), 7.89 
(s, 1H, H-5‘), 7.83 (d, J = 7.7 Hz, 1H, H-4), 7.54 (d, J = 8.4 Hz, 2H, H-2‘‘, H-6‘‘), 
7.46 (t, J = 7.7, 8.1 Hz, 1H, H-5), 7.33 (d, J = 8.1 Hz, 1H, H-6),7.12 (s, 1H, H-2), 
6.95 (bs, 2H, NH2), 6.93 (d, J = 8.4 Hz, 2H, H-3‘‘, H-5‘‘), 3.02 (s, 3H, SO2CH3). 
13
C 
 92 
NMR ppm: 160.9(s), 158.9(s), 158.0(s), 154.8(s), 138.9(s), 138.7 (s), 129.7(d), 129.5 
(d), 127.3 (s), 122.9(d), 121.4(d), 118.8(d), 117.3(s), 115.4(d), 109.0(d), 86.4(s), 
39.4(q). 
Anal. Calcd. for C19H16N4O3S: C, 59.99; H, 4.24; N, 14.73; S, 8.43; found: C, 60.03; 
H, 4.26; N, 14.79; S, 8.48. 
 
N-{3-[6-Amino-4-(2-hydroxy-3-methoxyphenyl)-5-cyano-pyridin-2-yl]-phenyl}- 
methanesulfonamide (46h) 
Yellow solid (82%), mp 240.5-241.4°C. 
1
H NMR ppm: 9.91 (s, 1H, NH), 7.90-7.83 
(m, 2H, H-4, H-5), 7.51-7.11 (m, 3H, H-6, H-5‘‘, H-6‘‘), 7.47 (s, 1H, H-3‘), 7.28 (s, 
1H, H-2), 7.20 (s, 1H, H-2‘‘), 6.98 (bs, 2H, NH2), 3.93 (s, 3H, OCH3), 3.06 (s, 3H, 
SO2CH3). 
13
C NMR ppm: 160.6(s), 160.5(s), 147.0(s), 144.7(s), 141.4(s), 139.1(s), 
138.7(s), 129.5 (d), 124.4(d), 123.2(d), 121.8(d), 119.1(d), 117.3(s), 115.7(d), 
114.3(d), 101.3(d), 99.4(s), 96.3(s), 56.0 (q), 39.4(q). 
Anal. Calcd. for C20H18N4O4S: C, 58.53; H, 4.42; N, 13.65; S, 7.81; found: C, 58.57; 
H, 4.43; N, 13.67; S, 7.84. 
 
N-{3-[6-Amino-4-(3-methoxyphenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46i) 
Brown solid (85%), mp 82.3-83.4°C. 
1
H NMR ppm: 10.02 (s, 1H, NH), 7.54-7.45 
(m, 2H, H-4, H-5‘‘), 7.41 (s, 1H, H-3‘), 7.37-7.33 (m, 2H, H-5, H-6‘‘), 7.20-7.19 (m, 
1H, H-4‘‘), 7.18 (s, 1H, H-2), 7.11-7-05 (m, 1H, H-6), 6.88 (bs, 2H, NH2), 6.82(s, 
1H, H-2‘‘), 3.82 (s, 3H, OCH3), 3.08 (s, 3H, SO2CH3). 
13
C NMR ppm: 159.1(s), 
154.0(s), 149.8(s), 149.3(s), 138.6(s), 138.4(s), 129.8(d), 123.7 (d), 120.7 (d), 
120.2(d), 118.8(d), 118.2(d), 115.(s), 115.1(d), 113.9(d), 94.3(d), 93.9(d), 55.2 (q), 
39.4(q). 
Anal. Calcd. for C20H18N4O3S: C, 60.90; H, 4.60; N, 14.20; S, 8.13; found: C, 60.92; 
H, 4.65; N, 14.17; S, 8.15. 
 
N-{3-[6-Amino-4-(4-diethylaminophenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46j) 
White solid (85%), mp 172.5-173.2°C. 
1
H NMR ppm: 10.05 (s, 1H, NH), 7.90-7.83 
(m, 2H, H-4, H-5), 7.51-7.11 (m, 3H, H-6, H-5‘‘, H-6‘‘), 7.47 (s, 1H, H-3‘), 7.28 (s, 
1H, H-2), 7.20 (s, 1H, H-2‘‘), 6.98 (bs, 2H, NH2), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, 
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OCH3), 3.03 (s, 3H, SO2CH3). 
13
C NMR ppm: 170.3(s), 150.8(s), 139.6(s), 134.6(s), 
132.1(d), 130.0(d), 124.1(d), 121.5 (d), 120.9 (s), 119.2(d), 116.8(s), 115.0(s), 
114.2(s), 111.6(d), 99.4(d), 74.0(d), 44.0(t), 39.4(q), 12.4(q).
 
Anal. Calcd. for C23H25N5O2S: C, 63.43; H, 5.79; N, 16.08; S, 7.36; found: C, 63.47; 
H, 5.82; N, 16.11; S, 7.38. 
 
N-{3-[6-Amino-4-(3,4,5-trimethoxyphenyl)-5-cyano-pyridin-2-yl]-phenyl}-
methanesulfonamide (46l) 
White solid (85%), mp 183.0-183.8°C. 
1
H NMR ppm: 10.05 (s, 1H, NH), 8.16-7.75 
(m, 2H, H-4, H-5), 7.44 (t, J = 7.9 Hz, 1H, H-6), 7.30 (s, 1H, H-3‘), 7.17(s, 1H, H-2), 
6.84 (s, 2H, H-2‘‘, H-6‘‘), 5.48 (bs, 2H, NH2), 3.93(s, 9H, OCH3), 3.06 (s, 3H, 
SO2CH3). 
13
C NMR ppm: 160.3(s), 158.5(s), 155.3(s), 153.5(s), 139.5(s), 137.4(s), 
131.9(s), 130.1 (d), 124.1 (d), 122.2(d), 119.8(d), 117.1(s), 111.0(d), 105.5(d), 
99.9(s), 88.6(s), 61.0(q), 56.3 (q), 39.6(q). 
Anal. Calcd. for C22H22N4O5S: C, 58.14; H, 4.88; N, 12.33; S, 7.06; found: C, 58.12; 
H, 4.83; N, 12.30; S, 7.08. 
 
6.2. Biology 
 
6.2.1. NCI Screening Test 
The human tumor cell lines of the cancer screening panel are grown in RPMI 
1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a 
typical screening experiment, cells are inoculated into 96 well microtiter plates in 
100 µL at plating densities ranging from 5,000 to 40,000 cells/well depending on the 
doubling time of individual cell lines. After cell inoculation, the microtiter plates are 
incubated at 37°C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to 
addition of experimental drugs. 
After 24 h, two plates of each cell line are fixed in situ with TCA to represent a 
measurement of the cell population for each cell line at the time of drug addition 
(Tz). Experimental drugs are solubilized in DMSO at 400-fold the desired final 
maximum test concentration and stored frozen prior to use. At the time of drug 
addition, an aliquot of frozen concentrate is thawed and diluted to twice the desired 
final maximum test concentration with complete medium containing 50 µg/mL 
gentamicin. Additional four, 10-fold or ½ log serial dilutions are made to provide a 
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total of five drug concentrations plus control. Aliquots of 100 µl of these different 
drug dilutions are added to the appropriate microtiter wells already containing 100 µl 
of medium, resulting in the required final drug concentrations. 
Following drug addition, the plates are incubated for an additional 48 h at 
37°C, 5% CO2, 95% air, and 100% relative humidity. For adherent cells, the assay is 
terminated by the addition of cold TCA. Cells are fixed in situ by the gentle addition 
of 50 µl of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 
60 min at 4°C. The supernatant is discarded, and the plates are washed five times 
with tap water and air dried. Sulforhodamine B (SRB) solution (100 µl) at 0.4% 
(w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 min at 
room temperature. After staining, unbound dye is removed by washing five times 
with 1% acetic acid and the plates are air dried. Bound stain is subsequently 
solubilized with 10 mM trizma base, and the absorbance is read on an automated 
plate reader at a wavelength of 515 nm. For suspension cells, the methodology is the 
same except that the assay is terminated by fixing settled cells at the bottom of the 
wells by gently adding 50 µl of 80% TCA (final concentration, 16% TCA). Using the 
seven absorbance measurements [time zero, (Tz), control growth, (C), and test 
growth in the presence of drug at the five concentration levels (Ti)], the percentage 
growth is calculated at each of the drug concentrations levels. Percentage growth 
inhibition is calculated as: 
 
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz 
 
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz. 
 
Three dose response parameters are calculated for each experimental agent. 
Growth inhibition of 50% (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, 
which is the drug concentration resulting in a 50% reduction in the net protein 
increase (as measured by SRB staining) in control cells during the drug incubation. 
The drug concentration resulting in total growth inhibition (TGI) is calculated from 
Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the 
measured protein at the end of the drug treatment as compared to that at the 
beginning) indicating a net loss of cells following treatment is calculated from [(Ti-
Tz)/Tz] x 100 = -50. Values are calculated for each of these three parameters if the 
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level of activity is reached; however, if the effect is not reached or is exceeded, the 
value for that parameter is expressed as greater or less than the maximum or 
minimum concentration tested. 
 
6.2.2. Hsp90 Inhibition Screening Tests 
17 AAG was obtained from Sigma-Aldrich. 
 
6.2.2a Cell Culture and Treatment 
MCF7 human breast cancer cells were obtained from the American Type 
Culture Collection (LGC Promochem, Middlesex, United Kingdom). Cells were 
grown in DMEM+GlutaMax1(Invitrogen) supplemented with 10% FBS, 50IU/mL 
penicillin, 50 µg/mL streptomycin and 1% non essential aminoacids and maintained 
in a humidified 5% CO2 incubator at 37°C. Exponentially growing cells were used 
for experiments. Each experiment was repeated at least three times. Culture medium 
with appropriate amounts of DMSO was used as control. Final DMSO concentration 
never exceeded 0.1%. 
 
6.2.2b Cell Proliferation Assay 
Cellular sensitivity to Hsp90 inhibitors was measured by methylene blue assay. 
The IG50 value was calculated as the concentration that inhibits cell proliferation by 
50% compared with vehicle controls. At the end of indicated time points, cells were 
collected and the living (trypan blue negative) and dead (trypan blue positive) cells 
were enumerated by counting using a hemocytometer. 
 
6.2.2c Cell Cycle Analysis 
Cell cycle effects were determined using propidium iodide (PI) staining and 
flow cytometry [76]. Briefly, the cells were collected and incubated in 200 µg/mL 
RNase A and 20 µg/mL PI for 15 min at 37°C. The DNA contents of more than 
10,000 cells were detected by FCM. Quantitative analysis of cell cycle distribution 
was performed using software. 
 
6.2.2d Western blot 
MCF-7 cells were rinsed twice with ice-cold PBS and harvested by scraping in 
ice-cold hypotonic lysis buffer (10 mM Hepes, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
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PMSF, 1.5 g/mL soya bean trypsin inhibitor, 7 µg/mL pepstatin A, 5 µg/mL 
leupeptin, 0.1 mM benzamidine and 0.5 mM DTT) and incubated for 15 min on ice. 
The lysates were centrifuged at 13,000 g for 5 min and supernatants (cytosolic 
fraction) were immediately portioned and stored at −80°C up to two weeks. Protein 
concentration was determined using the Bradford protein assay reagent (Bio-RAD, 
Milan, Italy) and 20 μg of protein was separated on 8-12% SDS-polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membrane. The immunoblot was 
incubated overnight at 4°C with blocking solution (5% skim milk), followed by 
incubation with an anti-cRAF (SC133, Santa Cruz, CA), anti-CDK4 (SC260; Santa 
Cruz, CA), anti-ErbB-2 (SC284; Santa Cruz, CA)  antibody for 1h at room 
temperature. Blots were washed two times with Tween 20/Tris-buffered saline 
(TTBS) and incubated with horseradish peroxidase (HRP)-conjugated anti-IgG 
antibody for 1h at room temperature. Blots were again washed five times with TTBS 
and then developed by enhanced chemiluminescence (Amersham Life Science, 
Arlington Heights, IL, U.S.A.). All membranes were stripped and reprobed for γ-
actin as control. 
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